CN117599140A - 一种降血糖、降血压、降血脂的中药组合物及其制备与应用 - Google Patents
一种降血糖、降血压、降血脂的中药组合物及其制备与应用 Download PDFInfo
- Publication number
- CN117599140A CN117599140A CN202311624084.1A CN202311624084A CN117599140A CN 117599140 A CN117599140 A CN 117599140A CN 202311624084 A CN202311624084 A CN 202311624084A CN 117599140 A CN117599140 A CN 117599140A
- Authority
- CN
- China
- Prior art keywords
- parts
- fried
- seed
- blood
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008280 blood Substances 0.000 title claims abstract description 167
- 210000004369 blood Anatomy 0.000 title claims abstract description 166
- 239000003814 drug Substances 0.000 title claims abstract description 134
- 239000000203 mixture Substances 0.000 title claims abstract description 86
- 230000001603 reducing effect Effects 0.000 title claims abstract description 62
- 230000036772 blood pressure Effects 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title abstract description 16
- 229940079593 drug Drugs 0.000 claims abstract description 59
- 210000000582 semen Anatomy 0.000 claims abstract description 56
- 235000009508 confectionery Nutrition 0.000 claims abstract description 45
- 241000173529 Aconitum napellus Species 0.000 claims abstract description 38
- 241000758794 Asarum Species 0.000 claims abstract description 36
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 33
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 30
- 235000017803 cinnamon Nutrition 0.000 claims abstract description 29
- 235000002732 Allium cepa var. cepa Nutrition 0.000 claims abstract description 27
- 235000006463 Brassica alba Nutrition 0.000 claims abstract description 26
- 244000140786 Brassica hirta Species 0.000 claims abstract description 26
- 235000011371 Brassica hirta Nutrition 0.000 claims abstract description 26
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 26
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 26
- 241000408747 Lepomis gibbosus Species 0.000 claims abstract description 26
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims abstract description 26
- 235000004347 Perilla Nutrition 0.000 claims abstract description 26
- 244000124853 Perilla frutescens Species 0.000 claims abstract description 26
- 235000020236 pumpkin seed Nutrition 0.000 claims abstract description 26
- 240000005979 Hordeum vulgare Species 0.000 claims abstract description 25
- 235000007340 Hordeum vulgare Nutrition 0.000 claims abstract description 25
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims abstract description 25
- 229940023019 aconite Drugs 0.000 claims abstract description 25
- 239000002994 raw material Substances 0.000 claims abstract description 25
- 241000801118 Lepidium Species 0.000 claims abstract description 24
- 235000003805 Musa ABB Group Nutrition 0.000 claims abstract description 21
- 235000015266 Plantago major Nutrition 0.000 claims abstract description 21
- 235000013305 food Nutrition 0.000 claims abstract description 20
- 235000001855 Portulaca oleracea Nutrition 0.000 claims abstract description 17
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 16
- 240000001972 Gardenia jasminoides Species 0.000 claims abstract description 14
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 12
- 235000018958 Gardenia augusta Nutrition 0.000 claims abstract description 12
- 239000002671 adjuvant Substances 0.000 claims abstract description 9
- 235000013409 condiments Nutrition 0.000 claims abstract description 4
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims abstract 7
- 240000008790 Musa x paradisiaca Species 0.000 claims abstract 6
- 244000234609 Portulaca oleracea Species 0.000 claims abstract 6
- 241000220259 Raphanus Species 0.000 claims description 24
- 150000002632 lipids Chemical class 0.000 claims description 17
- 235000021419 vinegar Nutrition 0.000 claims description 14
- 239000000052 vinegar Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 238000010298 pulverizing process Methods 0.000 claims description 12
- 241000220261 Sinapis Species 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 244000269722 Thea sinensis Species 0.000 claims description 8
- 241000721047 Danaus plexippus Species 0.000 claims description 7
- 238000004140 cleaning Methods 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 6
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 5
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 2
- 230000000055 hyoplipidemic effect Effects 0.000 claims description 2
- 241000234282 Allium Species 0.000 claims 5
- 230000000694 effects Effects 0.000 abstract description 96
- 244000291564 Allium cepa Species 0.000 abstract description 23
- 235000013361 beverage Nutrition 0.000 abstract description 4
- 240000006248 Broussonetia kazinoki Species 0.000 abstract description 3
- 244000088415 Raphanus sativus Species 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 description 69
- 210000004185 liver Anatomy 0.000 description 64
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 60
- 241000700159 Rattus Species 0.000 description 57
- 206010062717 Increased upper airway secretion Diseases 0.000 description 56
- 210000002216 heart Anatomy 0.000 description 56
- 208000026435 phlegm Diseases 0.000 description 56
- 210000004072 lung Anatomy 0.000 description 52
- 210000000952 spleen Anatomy 0.000 description 47
- 210000002784 stomach Anatomy 0.000 description 47
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 44
- 230000007812 deficiency Effects 0.000 description 43
- 206010012601 diabetes mellitus Diseases 0.000 description 38
- 241000699670 Mus sp. Species 0.000 description 33
- 230000001717 pathogenic effect Effects 0.000 description 32
- 208000002193 Pain Diseases 0.000 description 31
- 235000019197 fats Nutrition 0.000 description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
- 201000010099 disease Diseases 0.000 description 26
- 230000001737 promoting effect Effects 0.000 description 26
- 208000031226 Hyperlipidaemia Diseases 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 24
- 230000001965 increasing effect Effects 0.000 description 23
- 241000723347 Cinnamomum Species 0.000 description 22
- 235000012000 cholesterol Nutrition 0.000 description 21
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 20
- 210000003128 head Anatomy 0.000 description 20
- 230000017531 blood circulation Effects 0.000 description 18
- 210000000038 chest Anatomy 0.000 description 18
- 230000006870 function Effects 0.000 description 18
- 239000008103 glucose Substances 0.000 description 18
- 230000002829 reductive effect Effects 0.000 description 18
- 230000001105 regulatory effect Effects 0.000 description 18
- 239000003826 tablet Substances 0.000 description 18
- 208000024891 symptom Diseases 0.000 description 17
- 210000001835 viscera Anatomy 0.000 description 17
- 206010020772 Hypertension Diseases 0.000 description 16
- 240000005561 Musa balbisiana Species 0.000 description 15
- 230000035922 thirst Effects 0.000 description 15
- 208000006820 Arthralgia Diseases 0.000 description 14
- 210000001124 body fluid Anatomy 0.000 description 14
- 239000010839 body fluid Substances 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 14
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 14
- 240000003059 Portulaca quadrifida Species 0.000 description 13
- 239000000284 extract Substances 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 238000005728 strengthening Methods 0.000 description 13
- 210000002700 urine Anatomy 0.000 description 13
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 12
- 235000013350 formula milk Nutrition 0.000 description 12
- 150000004676 glycans Chemical class 0.000 description 12
- 230000002107 myocardial effect Effects 0.000 description 12
- 229920001282 polysaccharide Polymers 0.000 description 12
- 239000005017 polysaccharide Substances 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- 238000010792 warming Methods 0.000 description 12
- 241000219304 Portulacaceae Species 0.000 description 11
- 230000009471 action Effects 0.000 description 11
- 239000012530 fluid Substances 0.000 description 11
- 206010011224 Cough Diseases 0.000 description 10
- 238000009825 accumulation Methods 0.000 description 10
- 208000006673 asthma Diseases 0.000 description 10
- 210000004204 blood vessel Anatomy 0.000 description 10
- 239000000306 component Substances 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 10
- 235000019634 flavors Nutrition 0.000 description 10
- 230000001976 improved effect Effects 0.000 description 10
- 210000003205 muscle Anatomy 0.000 description 10
- 238000010926 purge Methods 0.000 description 10
- 210000003932 urinary bladder Anatomy 0.000 description 10
- 206010019280 Heart failures Diseases 0.000 description 9
- 108010028554 LDL Cholesterol Proteins 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 230000035487 diastolic blood pressure Effects 0.000 description 9
- 230000033001 locomotion Effects 0.000 description 9
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 8
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 8
- 206010030113 Oedema Diseases 0.000 description 8
- 102000004357 Transferases Human genes 0.000 description 8
- 108090000992 Transferases Proteins 0.000 description 8
- 208000031975 Yang Deficiency Diseases 0.000 description 8
- 229940039750 aconitine Drugs 0.000 description 8
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 8
- 230000004087 circulation Effects 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 230000004438 eyesight Effects 0.000 description 8
- 235000011194 food seasoning agent Nutrition 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 230000027939 micturition Effects 0.000 description 8
- 239000006187 pill Substances 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- 230000035488 systolic blood pressure Effects 0.000 description 8
- 239000002023 wood Substances 0.000 description 8
- TYPSVDGIQAOBAD-DZGCQCFKSA-N Atractylone Chemical compound C([C@]1(C)C2)CCC(=C)[C@@H]1CC1=C2OC=C1C TYPSVDGIQAOBAD-DZGCQCFKSA-N 0.000 description 7
- 206010010774 Constipation Diseases 0.000 description 7
- 108010010234 HDL Lipoproteins Proteins 0.000 description 7
- 102000015779 HDL Lipoproteins Human genes 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 102000019197 Superoxide Dismutase Human genes 0.000 description 7
- 108010012715 Superoxide dismutase Proteins 0.000 description 7
- 208000031971 Yin Deficiency Diseases 0.000 description 7
- 230000032683 aging Effects 0.000 description 7
- 230000001174 ascending effect Effects 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 230000002708 enhancing effect Effects 0.000 description 7
- 210000003414 extremity Anatomy 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- -1 phytosterol Substances 0.000 description 7
- 238000010791 quenching Methods 0.000 description 7
- 210000002435 tendon Anatomy 0.000 description 7
- 238000012795 verification Methods 0.000 description 7
- 239000000341 volatile oil Substances 0.000 description 7
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 6
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 6
- 206010000060 Abdominal distension Diseases 0.000 description 6
- 208000000059 Dyspnea Diseases 0.000 description 6
- 206010013975 Dyspnoeas Diseases 0.000 description 6
- 108010023302 HDL Cholesterol Proteins 0.000 description 6
- 240000007594 Oryza sativa Species 0.000 description 6
- 235000007164 Oryza sativa Nutrition 0.000 description 6
- 206010047700 Vomiting Diseases 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 6
- 229940117916 cinnamic aldehyde Drugs 0.000 description 6
- 229940109239 creatinine Drugs 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 210000002683 foot Anatomy 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 230000002685 pulmonary effect Effects 0.000 description 6
- 235000021251 pulses Nutrition 0.000 description 6
- 235000009566 rice Nutrition 0.000 description 6
- 239000002689 soil Substances 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 5
- 108010082126 Alanine transaminase Proteins 0.000 description 5
- 108010071619 Apolipoproteins Proteins 0.000 description 5
- 102000007592 Apolipoproteins Human genes 0.000 description 5
- 206010008479 Chest Pain Diseases 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 5
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 5
- 208000005392 Spasm Diseases 0.000 description 5
- 108090000340 Transaminases Proteins 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 229930013930 alkaloid Natural products 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 208000002173 dizziness Diseases 0.000 description 5
- 230000035622 drinking Effects 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 201000001421 hyperglycemia Diseases 0.000 description 5
- 230000001077 hypotensive effect Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 210000002429 large intestine Anatomy 0.000 description 5
- 230000003908 liver function Effects 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 230000000171 quenching effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000014898 transaminase activity proteins Human genes 0.000 description 5
- 230000002861 ventricular Effects 0.000 description 5
- 230000008673 vomiting Effects 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 206010008631 Cholera Diseases 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 4
- 206010033645 Pancreatitis Diseases 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 229960005261 aspartic acid Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 4
- 229960000830 captopril Drugs 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- 150000002212 flavone derivatives Chemical class 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 210000001624 hip Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000037356 lipid metabolism Effects 0.000 description 4
- 230000003859 lipid peroxidation Effects 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229960003105 metformin Drugs 0.000 description 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 4
- 235000012149 noodles Nutrition 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 206010036067 polydipsia Diseases 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000008171 pumpkin seed oil Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 210000004989 spleen cell Anatomy 0.000 description 4
- 238000010025 steaming Methods 0.000 description 4
- 210000004243 sweat Anatomy 0.000 description 4
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- 239000004278 EU approved seasoning Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 206010067171 Regurgitation Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 108010069201 VLDL Cholesterol Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 150000003797 alkaloid derivatives Chemical class 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- TYPSVDGIQAOBAD-UHFFFAOYSA-N atractylone Natural products C1C2(C)CCCC(=C)C2CC2=C1OC=C2C TYPSVDGIQAOBAD-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 235000008429 bread Nutrition 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 3
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 229940043353 maltol Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 150000002989 phenols Chemical class 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 2
- 108010064733 Angiotensins Proteins 0.000 description 2
- 102000015427 Angiotensins Human genes 0.000 description 2
- 102000015790 Asparaginase Human genes 0.000 description 2
- 108010024976 Asparaginase Proteins 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- IUCNQFHEWLYECJ-FNAJZLPOSA-L Atractyloside Chemical compound [K+].[K+].O1[C@H](CO)[C@@H](OS([O-])(=O)=O)[C@H](OS([O-])(=O)=O)[C@@H](OC(=O)CC(C)C)[C@@H]1O[C@H]1C[C@@]2(C)[C@@H]3CC[C@@H](C(=C)[C@@H]4O)C[C@]34CC[C@@H]2[C@H](C(O)=O)C1 IUCNQFHEWLYECJ-FNAJZLPOSA-L 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 206010008469 Chest discomfort Diseases 0.000 description 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 2
- 201000006306 Cor pulmonale Diseases 0.000 description 2
- 241001481833 Coryphaena hippurus Species 0.000 description 2
- 239000003154 D dimer Substances 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 206010051055 Deep vein thrombosis Diseases 0.000 description 2
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 2
- 208000035240 Disease Resistance Diseases 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 206010017711 Gangrene Diseases 0.000 description 2
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 description 2
- IBFYXTRXDNAPMM-FZEIBHLUSA-N Geniposide Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H]2[C@@H]1CC=C2CO IBFYXTRXDNAPMM-FZEIBHLUSA-N 0.000 description 2
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 description 2
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 description 2
- 208000025599 Heat Stress disease Diseases 0.000 description 2
- 206010019345 Heat stroke Diseases 0.000 description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 2
- 108010057186 Insulin Glargine Proteins 0.000 description 2
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 206010024642 Listless Diseases 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 206010062575 Muscle contracture Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ZYEMGPIYFIJGTP-UHFFFAOYSA-N O-methyleugenol Chemical group COC1=CC=C(CC=C)C=C1OC ZYEMGPIYFIJGTP-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 206010039424 Salivary hypersecretion Diseases 0.000 description 2
- 206010040925 Skin striae Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 2
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000003433 aortic smooth muscle cell Anatomy 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- VGLLGNISLBPZNL-RBUKDIBWSA-N arborescoside Natural products O=C(OC)C=1[C@@H]2C([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)=C(CO)CC2 VGLLGNISLBPZNL-RBUKDIBWSA-N 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- 229960003272 asparaginase Drugs 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 2
- FYQXODZRNSCOTR-UHFFFAOYSA-N atractyloside Natural products O1C(CO)C(OS(O)(=O)=O)C(OS(O)(=O)=O)C(OC(=O)CC(C)C)C1OC1CC2(C)C3CCC(C(=C)C4O)CC34CCC2C(C(O)=O)C1 FYQXODZRNSCOTR-UHFFFAOYSA-N 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960005233 cineole Drugs 0.000 description 2
- 235000021270 cold food Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000009695 di'ao xinxuekang Substances 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 238000002592 echocardiography Methods 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 108010052295 fibrin fragment D Proteins 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 230000007760 free radical scavenging Effects 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 2
- 201000008980 hyperinsulinism Diseases 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229960002869 insulin glargine Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000017971 listlessness Diseases 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- KIALCSMRIHRFPL-UHFFFAOYSA-N n-(2,5-diphenylpyrazol-3-yl)-4-nitrobenzamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(=O)NC1=CC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 KIALCSMRIHRFPL-UHFFFAOYSA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000024121 nodulation Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 2
- 235000012771 pancakes Nutrition 0.000 description 2
- 230000001314 paroxysmal effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 208000008494 pericarditis Diseases 0.000 description 2
- 229950007002 phosphocreatine Drugs 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 235000021395 porridge Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 201000007094 prostatitis Diseases 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000036593 pulmonary vascular resistance Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 210000002254 renal artery Anatomy 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 208000026451 salivation Diseases 0.000 description 2
- 208000021070 secondary pulmonary alveolar proteinosis Diseases 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000013555 soy sauce Nutrition 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 229940035722 triiodothyronine Drugs 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- RZPZLFIUFMNCLY-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol Chemical compound OC(=O)\C=C\C(O)=O.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 RZPZLFIUFMNCLY-WLHGVMLRSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 1
- 210000002925 A-like Anatomy 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 235000010167 Allium cepa var aggregatum Nutrition 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010002953 Aphonia Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000242722 Cestoda Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009126 Chronic respiratory failure Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 241000732800 Cymbidium Species 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000003849 Cytochrome P450 Human genes 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000380450 Danaus melanippus Species 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 206010013647 Drowning Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 241000218671 Ephedra Species 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 244000025361 Ficus carica Species 0.000 description 1
- 235000008730 Ficus carica Nutrition 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 241000935235 Fritillaria meleagris Species 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- ZJDOESGVOWAULF-OGJQONSISA-N Geniposidic acid Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(CO)=CC[C@@H]2C(C(O)=O)=CO1 ZJDOESGVOWAULF-OGJQONSISA-N 0.000 description 1
- VYAALAFRWREWLA-BVTMAQQCSA-N Geniposidic acid Natural products CCC1=CC[C@H]2[C@@H]1[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)OC=C2C(=O)O VYAALAFRWREWLA-BVTMAQQCSA-N 0.000 description 1
- ZJDOESGVOWAULF-UHFFFAOYSA-N Geniposidinsaeure Natural products OC1C(O)C(O)C(CO)OC1OC1C2C(CO)=CCC2C(C(O)=O)=CO1 ZJDOESGVOWAULF-UHFFFAOYSA-N 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 101800002372 Motilin Proteins 0.000 description 1
- 102000002419 Motilin Human genes 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 208000010359 Newcastle Disease Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 206010034498 Pericarditis uraemic Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 241001522129 Pinellia Species 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- 235000011230 Prunus domestica subsp. italica Nutrition 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037544 Purging Diseases 0.000 description 1
- 101100537532 Rattus norvegicus Tnni3 gene Proteins 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 244000249693 Reneklode Species 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- BZPMXJKRKXDRID-UOIKKKDVSA-N Scandoside Natural products OC[C@H]1O[C@@H](O[C@H]2CC=C([C@@H]3[C@@H](O)C=C(CO)[C@H]23)C(=O)O)[C@H](O)[C@@H](O)[C@@H]1O BZPMXJKRKXDRID-UOIKKKDVSA-N 0.000 description 1
- 241000242678 Schistosoma Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 208000019229 Spleen disease Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 201000001943 Tricuspid Valve Insufficiency Diseases 0.000 description 1
- 206010044640 Tricuspid valve incompetence Diseases 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 241001247821 Ziziphus Species 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 210000002403 aortic endothelial cell Anatomy 0.000 description 1
- RCHHVVGSTHAVPF-ZPHPLDECSA-N apidra Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CNC=N1 RCHHVVGSTHAVPF-ZPHPLDECSA-N 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- RJWJHRPNHPHBRN-FKVJWERZSA-N aucubin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(CO)=C[C@@H](O)[C@@H]2C=CO1 RJWJHRPNHPHBRN-FKVJWERZSA-N 0.000 description 1
- UTDFQMAXCUGNJR-UHFFFAOYSA-N aucubin Natural products OCC1OC(Oc2ccoc2C3C(O)CCC3O)C(O)C(O)C1O UTDFQMAXCUGNJR-UHFFFAOYSA-N 0.000 description 1
- 238000002555 auscultation Methods 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960005400 bisoprolol fumarate Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000025938 carbohydrate utilization Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 108091006003 carbonylated proteins Proteins 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- 235000020230 cinnamon extract Nutrition 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000037080 exercise endurance Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000030135 gastric motility Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 208000001288 gastroparesis Diseases 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 208000037809 hypertension grade 3 Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 108700039926 insulin glulisine Proteins 0.000 description 1
- 229960000696 insulin glulisine Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000002311 liver mitochondria Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 229940116837 methyleugenol Drugs 0.000 description 1
- PRHTXAOWJQTLBO-UHFFFAOYSA-N methyleugenol Natural products COC1=CC=C(C(C)=C)C=C1OC PRHTXAOWJQTLBO-UHFFFAOYSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000001452 natriuretic effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 208000005346 nocturnal enuresis Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000005426 pharmaceutical component Substances 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000009090 positive inotropic effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000002863 seminiferous tubule Anatomy 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 230000000920 spermatogeneic effect Effects 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 208000027140 splenic disease Diseases 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 235000019590 thick flavour Nutrition 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229960005461 torasemide Drugs 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000002385 vertebral artery Anatomy 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/34—Tea substitutes, e.g. matè; Extracts or infusions thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
- A61K36/268—Asarum (wild ginger)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种降血糖、降血压、降血脂的中药组合物,包括如下原料:去皮桂枝,江油附子,炒莱菔子,车前子,马齿苋,葱白,肉桂,北苍术,炒南瓜子,大麦芽,醋北五味子,炒白芥子,炒紫苏子,炒桅子仁,楮实子,细辛,炒甜葶苈子;其中,去皮桂枝、江油附子、炒莱菔子、车前子、马齿苋为君药;葱白、肉桂、北苍术、炒南瓜子、大麦芽为臣药;醋北五味子、炒白芥子、炒紫苏子、炒桅子仁为佐药;楮实子、细辛、炒甜葶苈子为使药。本发明还提供了上述组合物的制备与应用,并具体提供了一种袋泡茶。本发明中药组合物具有降血糖、降血压、降血脂功效,且可以加工成各种食品、饮品、调味品、保健品或药品形式。
Description
技术领域
本发明涉及中药制剂领域,尤其涉及一种降血糖、降血压、降血脂的中药组合物及其制备与应用。
背景技术
糖尿病在中医中属于“消渴”范畴。古人治疗“消渴”最经典的方法在《金匮要略》,但很少人对“经典治疗消渴”感兴趣,因很多现代医者认为消渴属于阴虚,尽用滋阴降火药治疗,其实不然,《金匮要略》最早提出治疗方药,开后世消渴治肾之先河。
目前,很多青少年、知识分子、中老年人得糖尿病,因环境、生活压力、劳心或禀赋不足、饮食失节、情志失调、三焦及五运六经气化和十二经络、经筋的失衡,劳伤营卫,因寒致郁而化热,心热移肺、热气蒸胸、胃壁坚燥、口喝、火燔土燥。其实,“消渴病”的病根就在厥阴,阴阳气不相顺接,脉微脏寒,厥深者热亦深。其病机在于:整体机能不足,内虚外强中干,整体虚寒,阳不化阴,阴虚为本(肺、脾胃、肾)以肾、肝虚寒为本。少阴病常合并痰饮瘀血等,肾为胃之关。
燥热(肺胃阳抗)为标,瘀血阻络,瘀浊不化,水湿泛滥,热毒壅积、阴损及阳,阴阳俱衰,病久入络,血脉瘀滞,脏腑虚损。
厥阴是阴阳之枢、病以寒为本,是因寒、饮之邪郁于半表半里,既不得外出,又不得入里,因呈上虚下寒,上热下寒,水虚不能化火,火虚不能化水的寒热错杂之证,而厥阴病邪无出路,故极易寒郁化热,少阳半表半里和阳明半表半里热往往交织在一起,少阳、少阴、太阴、阳明合并,甚至三阳三阴合并,半表半里在胸腹腔、空间广大是一切脏腑(也包括脾胃、肠、心肺、肝肾、膀胱等)所在之地。病邪在半表半里膏以下肓以上的脂类膜原三焦充斥,如长期服用现代医者所认为有效的“寒凉药、降火滋阴、益阴药或二甲双胍等西药”,没有给病邪出路就导致整个脏腑机能功能稳乱,极易引起很多脏器出问题,包括脏器的器质病变,而出现糖尿病的并发症。
糖尿病多作消渴论治,若以实火、阴虚、伤津为其主要病机,故取清火养阴、生津为例,受试160余例,用闭关止渴汤,人参白虎汤、益胃汤、消渴方、六味地黄丸、大补阴丸、泻心汤、消糖灵、清血八味汤方及西药二甲双胍等方辨证治疗者,虽临床症状有所改善,但尿糖及血糖无明显改变。
同时,随着社会的发展以及生活水平的提高,也有越来越多的人患有高血压、高血脂等疾病。
高血压是指血液在血管中流动时对血管壁造成的压力值高于正常值,其是最常见的心血管疾病之一,也是导致脑卒中、冠心病、心力衰竭等疾病的重要危险因素。在未使用降压药物的情况下,三次非同日测量血压值均高于正常,即收缩压≥140mmHg,和(或)舒张压≥90mmHg,即可诊断高血压。高血压的原因有两个:一,因寒凝、先是毛细血管痉挛或者下焦下肢的的血液微循环血管痉挛、最后大动脉也有痉挛,不仅仅是毛细血管堵了,大动脉也堵了,大脑要供血,心脏势必做出自我反应,加大压力给脑供血,这就形成了高血压;二:久寒成瘀,久寒化火化热,造成血流瘀滞,血液流动慢了产生各种代謝垃圾或血脂不能运输体外。
高血脂,寒湿生痰,痰浊凝滞导致血液淤堵,痰淤互结就形成高血脂。肝气郁积、气郁化火、肝旺乘脾,气血失于流泄郁积化脂。高油、高盐、高热量食物,在体内产生痰湿,全球温度变暖,湿度加大,凉吹冷饮,脾阳受损,无法运化水湿,聚湿成痰,就会导致寒湿之邪蕴于脾胃诱发高血脂。痰湿凝滞不利血行、气血运行受阻形成痰瘀附着于血脉就形成了高血脂,《脾胃论》指出:“脾胃不足,皆为血病”。
据此,可以古代相关药理为基础并结合现代药理研究,,调配出一种同时具有降血糖、降血压、降血脂功效的新型中药配伍组方。
发明内容
本发明所要解决的技术问题在于提供一种降血糖、降血压、降血脂的中药组合物及其制备与应用。
本发明采用以下技术方案解决上述技术问题:
一种降血糖、降血压、降血脂的中药组合物,包括如下重量份数的原料:去皮桂枝15~25份,江油附子25~35份,炒莱菔子25~35份,车前子45~55份,马齿苋25~35份,葱白10~20份,肉桂10~20份,北苍术10~20份,炒南瓜子25~35份,大麦芽55~65份,醋北五味子6~14份,炒白芥子5~13份,炒紫苏子6~14份,炒桅子仁6~14份,楮实子8~16份,(剪头去尾)细辛4~8份,炒甜葶苈子10~20份;其中,所述去皮桂枝、江油附子、炒莱菔子、车前子、马齿苋为君药;所述葱白、肉桂、北苍术、炒南瓜子、大麦芽为臣药;所述醋北五味子、炒白芥子、炒紫苏子、炒桅子仁为佐药;所述楮实子、细辛、炒甜葶苈子为使药。
作为本发明的优选方式之一,包括如下具体重量份数的原料:去皮桂枝18份,江油附子28份,炒莱菔子28份,车前子48份,马齿苋26份,葱白12份,肉桂12份,北苍术12份,炒南瓜子28份,大麦芽57份,醋北五味子7份,炒白芥子6份,炒紫苏子8份,炒桅子仁8份,楮实子10份,(剪头去尾)细辛5份,炒甜葶苈子13份。
作为本发明的优选方式之一,包括如下具体重量份数的原料:去皮桂枝20份,江油附子30份,炒莱菔子30份,车前子50份,马齿苋30份,葱白15份,肉桂15份,北苍术15份,炒南瓜子30份,大麦芽60份,醋北五味子10份,炒白芥子9份,炒紫苏子10份,炒桅子仁10份,楮实子12份,(剪头去尾)细辛6份,炒甜葶苈子15份。
作为本发明的优选方式之一,包括如下具体重量份数的原料:去皮桂枝23份,江油附子24份,炒莱菔子33份,车前子53份,马齿苋33份,葱白17份,肉桂17份,北苍术17份,炒南瓜子32份,大麦芽63份,醋北五味子12份,炒白芥子11份,炒紫苏子12份,炒桅子仁12份,楮实子14份,(剪头去尾)细辛7份,炒甜葶苈子18份。
一种上述降血糖、降血压、降血脂的中药组合物的制备方法,包括如下步骤:
(1)将去皮桂枝、江油附子、炒莱菔子、车前子、马齿苋、葱白、肉桂、北苍术、炒南瓜子、大麦芽、醋北五味子、炒白芥子、炒紫苏子、炒桅子仁、楮实子、细辛、炒甜葶苈子分别洗净,随后进行干燥、粉碎、灭菌,备用;
(2)按重量份数分别称取各原料进行混合,得目标所需中药组合物。
作为本发明的优选方式之一,所述步骤(1)中,粉碎至200目后灭菌备用。
一种上述降血糖、降血压、降血脂的中药组合物在食品、饮品、调味品、保健品、药品中的应用;其中,当其应用添加于食品时,可以是粥、面条、馒头、面包、饼干、月饼、糕点、粽子、大饼、冷食、膏类、米线、糖果等形式(但用于月饼、蛋糕、面包时,本发明作为枣泥、豆沙、果酱、果蓉的馅料);当其应用添加于饮品时,可以是酒、饮料等形式;当其应用添加于调味品时,可以是食醋、酱油、调料粉等形式;当其应用添加于保健品、药品时,可以是颗粒剂、片剂、胶囊、丸、口服液等形式。
一种袋泡茶,采用上述降血糖、降血压、降血脂的中药组合物。
作为本发明的优选方式之一,所述袋泡茶的具体制备方法为:将制得的所述降血糖、降血压、降血脂的中药组合物直接装入茶泡袋中。
作为本发明的优选方式之一,装入所述茶泡袋中的中药组合物计量具体为9g/袋。
本发明原料具体功效:
一、桂枝:性辛、甘,温;归心、肺、膀胱经。
(1)发汗解肌,温通经脉,助阳化气,治疗水湿不化、聚为痰饮、平冲降气。主治风寒风证,寒湿痹痛,四肢厥冷,癓瘕结块,胸痹,心悸,痰饮,小便不利,咳逆结气,补肝泻肺,行阳气于四表,调和营卫,化汗液,去邪闭,外彻腠理,甘辛大热,能宜导百药,通血脉,本品辛甘温煦,甘温通阳扶卫,善于宣阳气于卫分,畅营血于肌表,手足逆冷,气少脉弱,肾阳亏损,桂枝辛温,助阳化气,入肝胆,调木气,散郁遏,善治肝胆郁滞,肝风内动,桂枝透达营卫,故能解肌而风邪去,脾主营,肺主卫,甘走脾,辛走肺。入肝家而行血分,走经络而达荣郁,善解风邪,最调木气,升清阳之脱陷,降浊阴之冲逆,舒筋脉之急挛,利关节之壅阻。入肝胆而散遏抑。极止痛楚,通经络而开痹涩,甚去湿寒,能止奔豚,更安惊悸。和营、通阳、利水、下气、行瘀、补中。
(2)改善血液循环。桂皮醛刺激神经使皮肤血管扩张,改善外周循环,体外能够明显抑制胶原蛋白和凝血酶诱导的大鼠血浆中血小板的聚集,体内能够显著延长小鼠断尾后的出、凝血时间,减轻大鼠动脉旁路丝线上血栓的质量。
(3)本品含挥发油0.2%~0.9%,油中主要成是桂皮醛,占70~80%。经实验,其对麻醉大鼠具有显著的降血压作用,在120~360mg/Kg剂量范围内,能剂量依赖性地降低血压、左室收缩压(LVSP)和左室最大压力变化速率(dp/dtrnаx),且360mg/Kg桂皮醛对麻醉大鼠的心率(HR)也有显著抑制作用。离体血管灌流实验显示,桂皮醛在0.015~15mmol/L浓度范围内,可以剂量依赖性地舒张大鼠的胸主动脉。桂皮醛的降血压作用可能与桂皮醛对心肌的负性变时、变力效应和舒张血管作用有关。桂枝能解除毛细血管的收宿,降低血浆纤维蛋白原含量,降低血浆黏度,有助于血细胞表面电荷的充分暴露和变形活动,从而使全血黏降低,并能解除红细胞和血小板聚集,改善组织血液循环,消除肌浆网和许旺细胞内质网的水肿,使病变组织逆转修复,使心肌营养性血流量增加,对血小板聚集有抑制作用并有抗凝血酶作用。
二、江油附子:性辛、甘,大热;归心、肾、脾经;回阳救逆,补火助阳,散寒止痛;温散寒邪,振奋心阳。
(1)本品辛甘热,为纯阳燥烈之品,效力强大。能上助心阳以通脉,中温脾阳而散寒,下补肾阳以益火,能复散失之元阳,能回阳顷刻之间,为"回阳救逆第一品药"。治久病体虚,阳气衰微,阴寒内盛。本品辛甘温煦,有峻补元阳、益火消阴之效,逐退在内之阴寒,急回外越之阳气,消除格拒之势,故可治少阴病,阴盛于下,格阳于上,本品治肾阳不足,命门火衰所致阳痿宫冷,不孕不育。本品温脾、肾之阳,助气化而行水湿,故可治脾肾阳虚、阴寒内盛、水气不化之水肿,本品辛散温通,能通行十二经,并逐风寒湿邪,能温阳化气,助心行血,故可治阳不化气,湿痹胸阳所致胸痹,心前区阵发性绞痛。
(2)附子,入手少阳三焦、命门之剂,浮中沉,无所不至,味辛大热,为阳中之阳,故行而不止,回阳气,散阴寒,逐冷痰,通关节之猛药。诸病真阳不足,虚火上升,咽喉不利,饮食不入,服寒药愈甚者,附子乃命门主药,能入其窟穴而招之,引火归原,则浮游之火自熄矣。凡属阳虚阴极之侯,肺肾无热证者,服之有起死之殊功。附子味辛气温,火性迅发,无所不到,其性善走,外则达皮毛而除表寒,里则达下元而温痼冷,彻内彻外,凡三焦经络,诸脏诸腑,果有真寒无不可治。
(3)现代研究药理作用。
强心、抗心衰作用:离体蛙心实验研究结果表明,蒸煮8、10、12小时的附子具有强正性肌力作用,且心脏毒性显著降低,能增强冠状动脉流量和心肌收缩力。从附子水溶性成分首次分离得到一种新成分尿嘧啶,其5μg/乚剂量对蟾蜍离体心脏具有明显的增强心肌收缩速度作用。作用随剂量增加与时时延长而逐渐增强,且不影响心率,与合成品尿嘧啶对照,二者强心作用一致。附子粗制剂口服对动物有明显增强心肌收缩力和加快心肌收缩速度作用。附子成分去甲乌头碱有增强心肌收缩力作用,认为其是慢通道激动剂,属β受体部分激动剂。可能还有q受体兴奋作用,还可能促进神经末梢释放儿茶酚胺。附子可加快心力衰竭下鼠的心率、升高左心室内压,提高左心室内压最大上升和下降速率,改善心力衰竭大鼠血流动力学的变化,有明显的抗心力衰竭作用。附子苷有明显的强心作用,附子有通过剌激IL-2分泌来参与调节机体免功能的作用,附子水煎液能增强脾细胞、产生抗体,影像刀豆蛋白A(ConA)对脾细胞增殖反应作用。乌头碱增强巨噬细胞表面Iа抗原表达,提高其提交抗原能力,从而增强机体免疫应答反应。
(4)降血糖,乌头多糖可通过增加葡萄糖的利用而不提高胰岛素水平的机质产生降糖作用。
(5)附子有显著的平喘作用,很小剂量即能松弛豚鼠气管,并随剂量加大而作用增强。去甲乌药碱可明显对抗5-HT所致平滑肌痉挛,对抗组胺所致豚鼠呼吸道阻力增高。附子能增强虚寒记患者衰弱的新陈代谢功能。乌头碱能促进脑皮质的葡萄糖氧化,促进葡萄糖生成为乳酸以及增加耗氧量等。附子也能促进小鼠肝中蛋白质合成。去甲乌头药碱具有明显的抗氧化作用,能清除氧自由基,抑制脂质过氧化。
(6)经实验验证过,附子能提高大鼠血清总抗氧化能力(TAA)及红细胞超氧化物岐化酶(SOD)的ATPase的活性,可改善肝细胞膜脂流动性(LEU),附子能增强机体抗氧化能力,具有抗衰老作用。附子粗多糖和酸性多糖有显者的抑瘤作用,附子通过刺激IL-2分泌来参与调节机体免疫功能的作用,增强脾细胞产生抗体。具有明显的抗氧化作用,清除自由基,抑制脂质过氧化。
三、炒莱菔子:性辛、甘、平;归肺、脾、胃、大肠经;消食导滞,化气降痰。主治食积气滞,脘腹胀满,腹泻,下痢后重,咳嗽痰多,气逆喘满,攻肠胃积滞;治痰有推墙倒壁之功,炒用气香性温,其力能升能降,顺气开郁,消胀除满,下气定喘宽中,治痞块,利大小便。治疗便秘有良效、治疗消渴后变成水气,令作小便出。。
莱菔子含挥发油、多糖、酚类、生物碱、黄酮、植物甾醇、维生素及辅酶Q等。经验证,莱菔子注射液1.0mL/Kg(相当1g莱菔子生药)犬静脉注射1次,其体动脉收缩压(SAP)、舒张压(DAP)、体动脉平均压(MAP)分别降低10.9mmHg、13.9mmHg、2.15.2mmHg,肺动脉收缩压(SPAP)、肺动脉舒张压(DPAP)、肺动脉平均压(MPAP)亦降低。使体管阻力(SVR)、肺血管阻力(PVR)明显降低。并增加狗肢体血流量,说明其有扩张血管作用。椎动脉给药对兔猫均有降压作用,提示该药除通过对血管的直接扩张作用而引起降压外,并部分地通过中枢神经系统发挥其降压作用。降血压其作用缓和而持久,效果稳定重复性强,降血脂。
四、车前子:性甘,微寒,归肝、肾、肺、小肠经;清热通淋,渗湿止泻,明目,祛痰。主气癃,止痛,利水道小便,除湿痹;养肺强阴益精,清泄肝火而明目,疗赤痛;清上焦火热,导小肠热,止署湿泻痢,镇咳,祛痰,利尿,通便。
(1)化学成分:车前子含大量黏液质-车前子胶,属多糖类成分,其中含有L-阿拉伯糖、D-半乳糖、D-葡萄糖、D-甘露糖、L-鼠李糖、D葡萄糖及少量D-木糖和炭藻糖。还含有生物碱、蛋白质、氨基酸、环烯醚苷类化合物如桃叶珊瑚苷、京尼平苷酸、大量脂肪酸类、固醇类及酚酸类、微量元素等。车前子中富含Mg、Fe、AⅠ、Zn等元素,尤其是Mg含量高。
(2)药理作用:
降血脂作用:经验证,车前子能降低实验性高脂血症大鼠血清胆固醇、血清甘油三酯的含量,提高一氧化氮、高密度脂蛋白含量的同时,提高超氧化物岐化酶活性,可减轻脂质代谢紊乱,可对抗高脂血症大鼠脂质过氧化作用,对机体自由机的防御机能可产生一定的影响,具有调节血脂和保护高脂血症大鼠血管内皮细胞损伤的功能。
治疗老年人功能性便秘:车前子中等用量以上(>20g)具有通便作用。大剂量(50~70g)的通便作用更为明显,有效率90%以上,无副作用。车前子多糖可通过增强衰老模型大鼠脑自由基清除能力,降低AR我RAGE表达而抑制氧化酶糖基化,降低羰基化蛋白的产生和清除,降低脑组织单胺氧化酶2B含量而延缓脑衰老,车前子多糖是发挥抗衰退作用的主要成份。
五、马齿苋(一般为野生马齿苋):性酸,寒;归大肠、肝经经;清热解毒,凉血止痢。
(1)热毒血痢,疮疡丹毒,痈肿热毒。本品酸寒,入肝经血分,又清热凉血,治湿热凝滞、兼通入血破瘀,主诸肿瘘疣目,诸淋、金疮血流,破血癖癓瘕,痈疮疔肿、白秃及三十六种风结疮,破痃癖,止消渴。
(2)调节糖脂代谢。经验证,能明显改善2型糖尿病大鼠糖耐量和脂代谢紊乱,降低血清游离脂肪酸,减轻高胰岛素血症,提高胰岛素敏感性。长期灌服马齿苋多糖对四氧嘧啶所致糖尿病小鼠均具有降血糖作用,并能提高正常小鼠及四氧嘧啶所致糖尿病小鼠的糖耐量水平。马齿苋水煎液能降低高脂血症模型大鼠血清TC、TG、LDL及AI水平,并能提高HDL水平,且有调节高血脂症大鼠血脂代谢的作用。同时,能抑制胃轻瘫大鼠血浆胃动素(MTC)代偿性增高,具有缓解大鼠胃动力减慢的作用。抗动硬化、对神经系统保护,抗心率失常,调节肠胃功能,抗疲劳,抗炎、强心,降压,改善肝脏病理组织。抗疲劳,具有提高运动耐力,促进疲劳恢复效应,并能缓解因力竭运动引发的糖原耗竭、乳酸蓄积和能源障碍所致的细胞损伤。对肺癌、肝癌细胞细胞有较强的抑制作用。
(3)降血脂、抗动脉粥样硬化作用。野生马齿苋含有一种被称为α-亚麻酸的ω-3脂肪酸,它可能将胆固醇运输到其他组织进行正常代谢,避免在体内沉积,从而阻止血液中增高的脂质以各种形式侵入人动脉壁,引起平滑肌细胞增生,继而吞噬大量的脂质体成为泡沫细胞,防止动脉形成粥样硬化。经验证,马齿苋通过改善高脂血症家兔血脂代谢,使动脉硬化指数下降,有效地减轻主动脉壁粥样硬化形态学改变。马齿苋总黄酮以浓度依赖方式抑制大鼠主动脉平滑肌细胞(RASMC)增殖,抑制氧化型低密度脂蛋白诱导的RASMC增殖,并可诱导少量RASMC凋亡,从而发挥抗动脉硬化作用。
(4)本品含丰富的维生素A样物质,能促进上皮细胞功能的正常化及溃疡的愈合。马齿苋多糖可以增强细胞免疫,具有明显的抑瘤效果,具有抗衰老,延长寿命的作用,马齿苋提取夜能使肝超氧化物岐化氢酶(CAT)活性显著提高。
六、肉桂:性辛、甘,大热;归肾、脾、心、肝径;引火助阳,引火归原,散寒止痛,温经通脉。
(1)本品辛甘大热,温补肝肾,补火助阳,并能引火归原,益阳消阴,作用温和持久,为治命门火衰之要药。能外散寒邪,内温阳气,故可用治阳气素虚,寒邪直中三阴,四肢逆冷。能补肾火助肾阳,又能温中散寒。
(2)本品辛散温通,能通行气血经脉,散寒止痛,治肝肾两虚,风寒湿痹。温通胸中阳气,治阳虚寒凝,血滞痰阻所致的阴疽、流注。本品少量加入补气益血方中,有温运阳气、鼓舞气血生长的作用,本品有温阳通脉之功,亦可用治阴寒内盛,引动下焦冲气上凌心胸所致奔豚。
(3)补命门不足,益火消阴,治沉寒痼冷之药也。凡元虚不足而亡阳厥逆,或心肾久虚而痼冷怯寒,或奔豚寒疝而攻冲欲死,或气血冷凝而脉阻遏,假此味厚甘辛下热,下行走里之物,壮命门之阳,植心肾之气,宣导百药,使阳长则阴自消,而前诸症自退矣。
(4)对内分泌系统作用。经验证,肉桂水提物可抑制地塞米松阳虚小鼠的胸腺萎缩和肾上腺中胆固醇升高,其甲醇提取物能使大鼠肾脏β-肾上腺素受体的最大结合容量由正常转变为亢进。肉桂能提高雄性大鼠血浆睾酮水平并降低血浆三碘甲状腺原氨酸水平,但不影响血浆皮质酮水平。用大鼠附睾脂肪细胞实验发现肉桂能增强胰岛素活性3倍以上,有显著降低四氧嘧啶糖尿病小鼠的血糖作用。体内实验和体外实验均证实肉桂提取物有直接抗糖尿病作用。抑制肿瘤细胞增殖。
七、北苍术:性辛、苦,温;归脾、胃,肝经;燥湿健脾,祛风散寒,明目。
(1)性温散,发汗宽中,调胃进食,去心腹胀痛,霍乱呕吐,解诸郁结,逐山岚寒疫,散风眩头痛。消痰癖气块、水肿胀满。其性燥湿,故治冷痢冷泄滑泻、肠风、寒湿诸疮。
(2)气温味甘,入足阳明太阴经。能健胃安脾,主风寒湿痹、死肌痉疸,逐皮间风水结肿、心下满闷、腹中胀痛窄狭,消痰饮、痃癖、气块,祛疟,除瘟疫,山岚瘴气,止霍乱吐泻不止。治大风在身面、风眩头痛、目泪出、青盲雀目、内外翳障。久服乌须驻颜,壮筋骨,明耳目,润肌肤。
(3)脾精不禁,小便漏浊不止,腰背酸痛,苍术以敛脾精,精生于谷。苍术燥土利水,泄饮消痰,行瘀开郁,去漏化癖除湿,理吞酸去腐,辟岚川瘴疠,固筋骨之痿软,消溲溺之混浊。白术守而不走,苍术走而不守,白术善补,苍术善行,其消食纳谷,泄水开郁。
(4)气味雄厚,能彻上彻下,燥湿而宣化痰饮,最能驱除秽浊恶气,凡湿困脾阳倦怠嗜卧,肢体酸软,胸膈满闷,甚至胀而舌浊厚腻者,非茅术芳香猛烈不能开泄,而痰饮弥漫,亦非此不化。春秋之交,暑湿交蒸,湿温病寒热胀如裹,胸痞呕恶,脾家郁湿,足重跗肿,或积滞而便不利及湿热郁蒸,发为疮疡流注,或寒湿互结,发为阴疽酸痛,茅术为必需之品。能健脾安脾,诸湿肿非此不能除。治湿痰留饮及脾湿下流、浊沥带下、滑泻肠风。主风寒湿痹、死肌痉疸,作煎饵久服,轻身延年不饥。
(5)现代研究:
保肝作用:苍术水煎剂10g/Kg灌胃,连续7天,能明显促进正常小鼠肝脏蛋白的合成。苍术有效成分苍术醇、苍术酮、β-桉叶醇对四氯化碳诱发的一级培养鼠肝细细损害均有明显的预防作用。另外,苍术酮对叔丁基过氧化物诱导的DNA损伤及大鼠肝细胞毒性有抑制作。
降血糖:苍术苷对小鼠、大鼠、兔、犬有降血糖作用,其降血糖作用与苍术对体内巴斯德效应的抑制有关。它和腺嘌呤核苷酸在同一腺粒体受点上起竞争性抑制作用,从而抑制细胞内氧化磷酸作用,干扰能量转移。
降血压:北苍术根茎含挥发油1.5%,主要成分为苍术醇、苍术酮、茅苍术醇、桉油醇和a-没药醇等。经石油醚、乙酸乙酯、丙酮萃取后的苍术残渣对血管紧张素抑制酶具有强抑制作用,其抑制率为95.91%。产生降血压作用。
八、炒南瓜子(南瓜子,别名南瓜仁):性甘,平;归胃、大肠经;为绦虫驱除药,能杀蛔虫及血吸虫。治产后手足浮肿,对糖尿病患者亦有效。
(1)在动物实验中,南瓜子油(40mg/Kg)单独或与钙拮抗剂EeIodiPine(0.45mg/Kg)或血管紧张素转换酶抑制剂CaPtopriI(9mg/Kg)配合给予自发性高血压小鼠,结果显示南瓜子油可以改善小鼠体内自由基清除剂的含量,调节Ee1odipine与CaptoPri1的影响,延缓高血压进程。
(2)用Ereund’s完全佐剂诱导老鼠产生关节炎,给造模老鼠富含抗氧化剂成分的南瓜子油,结果表明南瓜子油如同吲哚美辛一样有效。
(3)对喂食造模的高胆固醇兔子,用辛伐他汀(simvatatin)和南瓜子油联合用药3周。可以降低血清总脂质水平,甘油三酯、总胆固醇和LDL-胆固醇均下降。
(4)经实验,治疗前列腺炎,口服南瓜子配合按摩关元穴治疗慢性前列腺炎,并以诺氟沙星治疗为对照组,结果治疗组在疼痛,滴白、排尿、性欲、阳痿、早泄、遗精等主要临床症状都有不同程度的改善。其中,临床治愈率者占总病例的27%,显效者占8%,有效占6%,无效者占4%,总有效率达41%。而对照组总有效率仅为15%。同时,治疗组在控制炎症、减少前列腺液白细胞方面也较对照组效佳,并能预防肾结石和治疗膀胱刺激征。
九、生(炒)大麦芽:性甘,平;归脾胃经;行气消食,健脾开胃,回乳消张;可升可降,入足太阴、阳明、手阳明经。本品能疏肝解郁,治肝气郁滞或肝胃不和之胁痛。炒香开胃,生用力猛,主消麦面食积,癓瘕气结,胸膈胀满,郁结痰涎。小儿伤乳,又能行上焦滞血,兼能利二便,虽为脾胃之药,而实善舒肝气,夫肝主疏泄,为肾行气,为其力能舒肝,善助肝木疏泄以行肾气。
(1)降血糖。经验证,麦芽浸剂口服可使家兔与正常人血糖降低,麦芽渣水提醇沉精制品制成的5%注射液,给家兔注射200mg,可使血糖降低40%或更多。
(2)抗氧化。经验证,2mmol/L麦芽酚保护人神经瘤细胞2小时后,对细胞膜蛋白和DNA的损伤均有明显的保护作用,减少了膜蛋白的氧化和细胞DNA片段化的形成,细胞线粒体功能损伤减小,细胞表达的白介素-6减少,被激活的细胞核因子кB水平同时降低。表明麦芽酚可以有效保护活性氧对神经细胞的氧化损伤,维持细胞的正常生理功能。
(3)经实验,高脂血症模型小鼠喂以大麦胚芽,能显著降低其血清胆固醇及三酰甘油含量,同时也抑制高脂食诱导的小鼠肝组织胆固醇、三酰甘油及过氧化脂质含量的增加。
十、醋北五味子:性酸、甘,温;归肺、心、肾经;收敛固涩,益气生津,补肾宁心。
(1)入手太阴,足少阴经。巜日华子》曰"明目,暖水脏,治风、下气、消食、霍乱转筋,痃癖本豚冷气,消水肿,反胃,心腹气胀,止渴、除烦热,解酒毒,壮筋骨"。《本草备要》曰其"专收肺气而滋肾水"。五味子酸能收敛,性温而润,上能敛肺气,下能滋肾阴,《神农本草经》曰能"主益气,补不足″。《本草备要》曰能"益气生津……除烦渴"。五味子甘以益气,酸能生津,有良好的益气养阴生津止渴的功效。治热伤气阴,心悸脉虚,口渴汗多。阴虚内热,口渴多饮。
(2)五味子既能收敛心气,滋肾补阴,又能宁心安神,治阴血亏损,心神失养,心肾不交。《本草经疏》:“五味子主益气者,气虚则上壅而不归元,酸以收之,摄气归元,则咳逆上气自除矣。劳伤羸瘦,补不足,强阴,益男子精”。《别录》:“养五脏,除热,生阴中肌者,五味子专补肾,兼补五脏,肾藏精,精盛则阴强,收摄则真气归元,而丹田暖,腐熟水谷,蒸糟粕而化精微,则精自生,精生则阴长,故主如上诸疾也”。
(3)现代研究:
降低血糖作用:从五味子中分离得到α-葡萄糖苷酶抑制剂,药理实验表明具有良好的降糖作用,它能明显降低正常及四氧嘧啶糖尿病小鼠的血糖,降低肾上腺素引起的高血糖,提高正常小鼠的糖耐量。五味子有增高心肌细胞内核糖核酸的作用,能提高心肌细胞、心脏小动脉和肾脏小动的ATP、5+N和碱性磷酸酶及心肌细胞线粒体内琥珀酸脱氢酶、葡萄糖-6-磷酸酶的活性。五味子有加强和调节心肌细胞和心脏、肾小动脉的能量代谢,改善心肌营养和功能等作用。实验还表明,五味子有抗肾病变作用,其木质素对免疫性肾炎呈抑制作用。取五味子2~3g/Kg腹腔注射,可以显著增加小鼠睾丸的重量提示了对小鼠性功能具有一定的促进作用。五味子水提液使成年小鼠睾丸重量增加了57.1%,使曲精管直径增加41%,且光镜下生精细胞的层数及精子的数量有所增加,证明五味子有促进精子发育作用。五味子多糖可使衰老小鼠己萎缩的胸腺及脾脏明显增大增厚,胸腺皮质细胞数及脾淋巴细胞数量明显增加,可明显促进衰老小鼠神经细胞的发育,能增强腹腔巨噬细胞吞噬功能。显著提高小鼠血清溶血素水平,且具有较好的免疫增强作用。
十一、炒白芥子:性辛,温;归肺胃经。利气燥痰,散结消肿;主治咳喘痰多,胸满协疼,肢体麻木,关节肿痛,湿痰流注,阴肿毒。
(1)利胸膈痰,止翻胃吐食,痰嗽上气,中风不语,安五脏,止夜多小便,能祛冷气,逐膜膈之痰,消癖化疟,降食定喘,利窍明目,逐瘀止痛,俱能凑效。补肝泻肺,动专行痰,去支饮温中开胃。
(2)通经络,散水饮,治喘嗽,皮里膜外之痰涎,非斯不达,胁下胸前之气滞,藉此而疏。
(3)白芥子味辛辣,横行甚捷,体细通行甚锐,专开结痰,痰属热者能解,属寒者能散,痰在皮里膜外,非此不达,在四肢两胁,非此不通,治结胸证,痰涎邪热固结胸中及咳嗽失音。利气宽中。
(4)或疑白芥子止能消膜膈之痰而不能清肺胃之痰,似乎消肺之痰必须贝母,消胃之痰必须半夏也,而谁知不然,夫膜膈之痰,经胃肺而言之也。胃肺中之膜膈,尤善藏痰者也,白芥子消膜膈之痰,凡是有痰之处,无不尽消,泥肺胃浅近之间,岂有反不能消之理?盖辛能入肺,温能散表,痰在胁下皮里膜外,得此辛温以为搜剔,则内外宜通而无阻隔窠囊留滞之患矣。
(5)“白介子其性降收,其用温散,故每于凝结之患而得开发,于逆上之穷而得降析,不止以利气豁痰竞其功也”。膜原半表半里以除之。
十二、炒紫苏子:性辛,温;归肺大肠经;降气,消痰,平喘,润肠;主治痰壅气逆、咳嗽气喘、肠燥便秘、调中、益五脏、下气、止霍乱、呕吐、反胃,虚劳,肥健人,利大小便;破癓结,消五隔、止嗽,润心肺,消痰气。治风顺气,利膈宽肠,定喘消痰降气,子乃和而降;清气开郁,散气甚捷,最能清利上下诸气,定喘痰有功,并能通二便,除风寒湿痹;消瘀顺气,气顺则膈利,宽肠亦以其润而降也。
同时,现代研究发现,紫苏子脂肪油有明显的降血脂作用。经实验,大豆肽和紫苏子油制成的制剂降脂肽可以显著降低高血脂模型大鼠的血清中TC及TG浓度,明显升高HDI-C水平,紫苏油对鼠脂代谢紊乱有预防作用,对高脂血症有一定的调整作用。紫苏子还有抗衰老、抗过敏.抗血小板聚集等作用。治疗慢性阻塞性肺气肿,慢性呼吸衰竭.肺心病心力衰竭及治疗慢性气管炎的急性发作。
十三、桅子仁(生用或炒用):性,苦,寒;归心、肺,胃,三焦经,胞络六经。疗目热赤痛、胸心大小肠大热,心中烦闷,胃中热气(热气蒸胸),除热及消渴口干,治热厥心痛,解热郁、行结气,伤寒劳复,敛相火妄行,渝三焦之水道。同时,佐大麦芽治肝胆郁火,治胃中热气,既亡血.亡津液.脏腑无润养,内生虚热非此物不可去,肺气清而化,膀胱为津液之腑,小便得此气化而出。清泻三焦火邪,主五内邪气,入手少阴心,足太阴脾,足厥阴肝,足太阳膀胱经,清心火除烦郁,泻脾土而驱湿热,吐胸膈之浊瘀,退皮肤之熏黄,苦寒涤瘀郁之热,独取其肃降之气,以敷条达之用。
(1)保肝。桅子提取液和桅子黄色素能够抑制CCI4所引起的急性肝损伤小鼠血中HLT和AST活性的升高,减轻肝细胞变性和肝小叶内的灶性坏死。桅子苷具有显著的保肝作用,其作用机制为抑制小鼠肝脏内细胞色素P450-EI的活性,降低自由基的生成速率和增加肝细胞内谷胱甘肽-s-转移酶以谷胱甘肽还原酶的活性,增加谷胱甘肽系统对CCI4的清除能力和速率。桅子苷还能降低酒精所致小鼠的死亡率。
(2)利胆。大鼠十二脂肠内给予桅子苷1g/Kg及2g/kg分别于5小时、2小时后对胆汁分泌呈显著的持续促进作用。
(3)对心血管作用。桅子提取物能降低心肌收缩力。桅子仁的热水提取物能刺激体外培养的牛主动脉内皮细胞的增殖,50μg/mL桅子仁的热水提取物能有效地增进3H胸腺嘧啶脱氧核苷和亮氨酸的掺入,表明可显著增加细胞中DNA和蛋白质的合成。
(4)促进胰腺分泌对胰腺功能的影响。经验证,桅子苷有显著的降低胰淀粉酶的作用,而其酶解产物都桷子素的增加胰胆流量作用最强,持续时间较短。桅子仁能提高胰腺炎时机体的抗病能力,减轻胰腺炎症程度并有稳定胰腺炎时腺泡细胞膜的作用,可使急性胰腺炎时期明显降低的大鼠胰腺细胞内琥珀酸脱氢酶升高,升高的酸性磷酸酶释放率明显降低,细胞内细胞色素P450增高,增强了胰腺炎时胰腺腺细胞抗病能力。
十四、楮实子:性甘,寒;归肝肾经;补肾清肝,明目利尿;滋阴血,清虚热。主阴痿水肿,益气、充肌肤,明目。壮筋骨,助阳气,补虚劳,助腰膝,健脾养肾,益智安神,调节内分泌失调,增强免疫。
(1)抗氧化。楮实子红色素能显著清除超氧阴离子及羟基自由基,抑制H2O2诱导小鼠红细胞溶血和肝勻浆自氧化,对肝线粒体有保护作用。
(2)降血脂。经实验,老年人痴呆患者使用楮实子后血清清中LPO、TC和TG水平较药用前显著下降,而SOD和HDL水平显著升高。
十五、细辛:性辛,温;归心、肺、肾经;祛风散塞,祛风止痛,通窍,温肺化饮。
(1)本品辛达肾气而润肝燥,辛温发散,芳香透达,散寒力胜,达表入里。入肺经既散在表之风寒,辛温走窜,芳香最烈,宣泄郁滞,上达巅顶,通利九窍,善治头面诸疾,为通窍止痛的要药。本品辛散温通,既可外散表寒,又能下气破痰,温肺化饮。细辛为散邪消痰涤饮之佳品、主“百节拘挛,风湿痹痛,死肌”,故本品为通痹散结要药。细辛既散少阴肾经在里之寒邪以通阳散结,又搜筋骨之间的风湿而蠲痹止痛,故善治气血亏虚,肝肾不足,腰膝冷痛,屈伸不利,畏寒喜温,久痹不愈。
(2)本品辛温走窜,散表里寒邪以温经,活血通脉以止痛,用治阳虚血弱,寒份经络,气血凝滞,手足厥寒,腰、股、腿、足疼痛,温肾暖脾,以除脏寒,味辛制蛔杀虫,盖“虫得辛则伏”。本品辛香走窜,上行乳脉,散结止痛,治肝郁气滞,乳汁不下,乳结胀痛,下行血海,温经暖宫,辛能泄肺、补肝、润燥,故通少阴及耳窍,本品辛达肾气而润肝燥。“细辛,芳香最烈,故善开结气,宣泄郁滞,而能上达巅顶,通利耳目,旁达百骸,无微不至,内之宣络脉而疏通百节,外之行孔窍而直达肌肤”。
(3)细辛,风药也,禀天地阳升之气以生,故其味辛温无毒,入手少阴太阳经。风性升,升则上行,辛则横走,温则发散,故主咳逆,头痛脑动,百节拘挛,风湿痹痛,死肌,盖痹及死肌,皆是感地之湿气也。
(4)细辛,禀少阴泉下之水阴,而上交于太阳之药……久服则水精之气濡空窍,故明目,利九窍。九窍利则轻身而长年。细辛气清而不浊,故善降浊气而升清气。
(5)细辛,味辛气温,达肾肝之阳气,力更猛于麻黄,是以在至阴之分,虽不同于补阳诸味,然能就阴分而散寒邪:既在至阳之分,虽难比于行气诸剂,然亦能就阳分而散阴结。
(6)细辛、盖邪之中人,无所依附,则其去必速,焉有绵延迁变如是哉,惟饮为邪窟宅,邪为饮凶锋,互相勾留,故其治虽至变端叠出,干姜能熯饮,不能去附饮之邪,附饮之邪不去,纵使饮己消而邪固在,亦终不渴,此则细辛之功,远在干姜之右矣。
(7)少阴脉不至头,然有痛者,为阴寒盛气所逆也,太阳经气为少阴寒气所郁,则病及于督。细辛散内寒而通真阳,故治督病。
(8)细辛味辛气温,禀阳升之性,辟除风寒湿邪,而芳香最烈,凡当心结痛,胁肋支撑,心痛彻背,背痛彻心等症,属于饮邪凝聚,大气不同旋运者,非温和燠煦不为功。细辛禀阳和之气,助其乾运,温肾通阳,则水道自利。
(9)华细辛所含的挥发油2.75%,主要成分为甲基丁香油酚(约含50%),猫股静脉注射可引起血压下降,一般可达20~30mmHg,煎剂0.1~0.4g/Kg静脉注射麻醉犬,表现出缓慢、温和的降压作用。细辛5g/Kg给小白鼠灌胃,连续10日,可抑制新城疫病和ConA诱导的小鼠脾细胞产生α等干扰素。细辛可以使小鼠的生精小管增粗,生精过程活跃。生精细胞增多,间质细胞增多,明显抑制衰老小鼠血清睾酮含量下降,此外细辛水提物0.4g/mL,对人乳头瘤病毒有破坏作用。
十六、炒甜葶苈子:性辛、甘,寒;归肺,膀胱经;泻肺平喘,虽泄肺而不伤胃,痰饮喘嗽,结胸等症。主癥瘕积聚结气,饮食寒热,破坚逐邪,通利水道。下膀胱水,伏留热气,皮间邪水上出,面目浮肿,身暴中风热痔痒,利小便。为手太阴经正药,亦入手阳明、太阳经。肺气壅塞则膀胱与焉,譬之上窍闭则下窍不通,下窍不通,则水湿泛溢为喘满、肿胀、积聚、种种之病生矣。葶苈滑润而香,专泻肺气,泻肺.泻水,凡积聚寒热从水气来者,葶苈之泻从上焦始。
(1)调血脂作用。经实验,甜葶苈子醇提取物和葶苈子油给饮食性高脂血症大鼠灌服,可降低高脂血症大鼠的总胆固醇、三酰甘油、低密度脂蛋白等,升高高密度脂蛋白水平等,具有明确调血脂作用。具体地,南葶苈子提取物能显著降低高脂血症大鼠的TC、TG、LDL-C、HDL3-C水平及LDL-C/HDL-C比值,显著升高HDL-C、HDL2-C水平及HDL-C/TC比值,起到降脂作用。
(2)治疗尿毒症性心包炎。经实验,在血液透析后每星期15小时,每次5小时,以及肝素、泼尼松等西医药治疗的基础上,加用:葶苈子30g,大枣5枚,每日1剂,水煎服,15日为一疗程,其治疗80例,经1个疗程治疗后治愈(临床症壮消失,超声心动图检杳心包炎较完全好转)68例,好转(临床症状好转,超声心动图检查心包炎)12例,全部有效。
(3)治疗肺心病心衰、慢性心力衰竭的效果良好。
十七、葱白:性辛,温。归肺、胃经。发散解表,通阳散寒,解毒散结。
(1)阴盛格阳,厥逆脉微,葱白辛散温通,宣通阳气,温散寒凝,可使阳气上下顺接、内外通畅。
(2)入太阴、阳明经,皆取其发散通气之功;通气故能解毒及理血病;气者,血之帅也;气通则血活。
(3)葱,辛能发散,能解肌,能通上下阳气;皆治外来怫郁诸证;散肝中邪热,除肝邪气,邪气散则正气通,辛润利窍。
(4)抗心肌缺血,白提取物能明显降低急性缺血性心肌缺血程度,缩小缺血心肌的梗死面积(MIS),降低血清中磷酸肌酸激酶(CK)、磷酸肌酸激酶同工酮(CK-MB)、肌钙蛋白I(cTnI)的活性。葱白提取物能明显保护缺血再灌注造成的心肌损伤,其机制可能是通过减轻缺血再灌注心肌细胞内游离钙浓度的增加而发挥上述作用。
(5)抗血栓形成,葱白提取物能改善兔创伤下肢深静脉血栓成模型的凝血功能,减少血浆凝血酶调节蛋白(TM)和D-二聚体(D-D),调节组织型纤溶酶原活化剂(t-PA)、纤溶酶原活化剂抑制物之间的相对平衡,从而防治创伤后深静脉血栓刑成。
“消渴”病症分析与本发明原料作用机理:
一、厥阴之为病:肝之经也,肝气郁结,肝血亏虚是消渴发病的内在因素;肝失疏泄,是消渴发病的病理机制,肝郁肝虚,湿热内生,痰瘀交阻是消渴证变证发生的根源。消渴者,因下寒木陷风动火郁,合邪刑金,肺津枯燥伤阴,津液失于敷布,则脾胃、肾失其濡养滋润。肺主气,为水之上源,肺受燥热所伤,津液不能敷布而直趋下行,随小便排出体外,小便数频量多,肺不布津则口渴多饮。厥阴脏气,自下上行,病则郁陷,怒气上冲,于是胸中疼热,木郁克土,脾陷则胃逆,故饥不欲食,木郁下寒、土陷木贼,风木遏陷,脾蒙其虐,胃为水海之谷,胃热亏耗,上灼肺液,脾为行其津液,脾阴不足,下耗肾阴,胃主腐熟水谷,脾主运化,为胃行其津液,脾胃受燥所伤,胃火炽盛→口渴多饮,多食善饥,脾气虚不能转输水谷精微,下流注入小便,水谷精微不能濡养肌肉,形体日渐消瘦,脾阴不足,故小便味甘。肾为先天之本,主藏精而寓元阴元阳,肾阴亏虚,虚火内生,上燔心肺,则烦渴多饮,中灼脾胃则胃热消谷,肾失濡养,开阖固摄失权,水谷精微直趋下泄,随小便排出体外→尿多味甜。肾与心肺…水火相济,金水相互,肾与脾胃,肾水先亏则胃失援,消渴:人体水液代谢必须以三焦为通,原以三焦气化,元气者,根于肾系于命门,乃通过三焦布散全身,从而推动和激发脏腑功能活动,肾虚元气不足,则三焦气化失职,肾为胃关,肾虚开关不合,则水下无止,水液有降无升则尿多,水液不能蒸腾气化为津,则口渴多饮。精微失布散,谷气下流则肌体失于充养,故形瘦而食。命门火衰,火不温土则脾胃运化失司,火不温肾,则肾阳虚而水不化,肾暖则气上升而润肺,肾冷则气不上升而肺焦。火不暖肝,则肝阳升发不足,命门火衰则心阳不振,血脉不温则血流瘀缓,命门火衰也会导致肺卫阳虚,卫外不固易致客邪入侵,引发种种合并症。火强则生肌壮,火衰而生肌弱,火灭则人亡。命门为十二脏腑之根,为生命之源,命门之火是先天无极之火,火与真水相济,永不相离,阴阳根系于水火,命门的水火即人体的阴阳,五行生克制化,实为命门水火功能的演化。
二、消渴分为下消(下焦)、中消(中焦)、上消(上焦)。
下消(下焦):“肾苦燥”,急食辛以润之。本发明的组合物,桂枝、细辛、肉桂、附子,开腠理至津液上通下彻,脾家得附子则能土,而水有所归,肾得附子则坎阳鼓动、而水有摄。附子大热纯阳、补先天之火种,肾暖则气上升而润肺,肾冷则气不升而肺焦,佐肉桂以温中焦之土气而调和上下,引火归元,下行走里,能引离中之阴,下交于肾,附子又能启水中之阳,上交于心,阴阳交媾,而水火互根矣,辛能润肾、补肝、泻肺、润燥、补胃气、生水液,振奋细胞机能。细辛佐枝桂能驱脏腑之寒,佐附子能散诸疾之冷,善开结气,宣泄郁滞、而能上达巅顶,通立耳目,旁达百骸,无微不至,内之宣络脉而疏通百节,外行孔窍而直达肌肤,以通达气机。炒桅子仁、麦芽治厥阴,不能食而气冲,肝火最横,燔灼无忌,耗伤津液,水木合邪凌侮弱土,以胆木而克胃土,以肝木克脾土,脾本不利、有肝木以泻之,则下利、呕利者,虽脾胃之病。而实肝胆之邪也,水木侵凌,土崩阳败。气陷而不升导致消渴,桅子仁治心热移肺,热气蒸胸,胃壁坚燥.口喝,火燔土燥助大麦芽治疗阴盛阳虚,阳盛阴虚,血行气机不畅,阳不化阴,阴阳气不相顺接。治肝胆郁火,木火型金,敛相火忘行,渝三焦之水道,涤瘀郁之热,独取其降肃之气,以敷条达。野生马齿苋、葱白、桂枝、(剪头去尾)细辛、肉桂、附子共温肾阳,见萤光,温存中气,中气苏.照濡长养,而阳和四布,上下升沉。肾阴摄水,从阴中温养其阳,肾气上蒸、津液上承,破血逐瘀、溶栓、通行十二经、深入百络、瘀血在里,故其不得通,不能载津液上升则口渴,瘀去则通而不渴。通的是毛孔,血管、七窍、经络、淋巴、肌筋膜和二便、三焦阴阳、上下相顺接,通则无堵百病消。
中消(中焦):炒莱菔子、车前子、苍术、炒白芥子、炒紫苏子,劳伤营卫,劳心过度,压力应激,七情内伤郁而化热,热气蒸胸,胃壁坚燥,缺乏津液的滋润,火燔土燥而出现口渴。涤痰清气开郁,内外宣通,消瘀顺上下诸气。治阳明腑实之热厥、热结,承顺胃气下行,六腑以通为用,胃气以降为顺,可使塞者通,闭者畅。
上消(上消):醋北五味子、甜葶苈子、南瓜子、楮实子,用于心热移肺,营卫两虚,营气不足燥热内生形成消渴。“心营肺卫“,养肺降心、滋肾益脾、敛肺,五味子通行水液,补五脏,统领五脏六腑,经络腧穴,三焦者元气之别使,水液之通道。葶苈子破坚逐邪,通利水道,破滞开结,泻肺,肺为水之上源,主皮毛、司呼吸、朝百脉、下萌肾水,通调水通,下输膀胱,水精四布,五经并行,使三焦水液代谢通道畅,上焦得通,胃气阴和,津液得下,桂枝通行血液、麦芽、醋五味子通行水液,楮实子补充糖尿病因整体机能营养物质的匮乏和功能的不足。诸药合力,粘膜、腺体、细胞膜、络膜、半表半里(三焦)得以阴阳相顺接,使道路散而不结,津液生而不枯、气血利而不涩,改善细胞膜环境,保护细胞膜蛋白和DNA的形成,促进造血干细胞生成。达到治愈消渴病和预防消渴、高血脂、高血压的目的。本发明的中药组合物降糖机理,促进糖的利用,刺激胰岛细胞分泌胰岛素,改善组织细胞的胰岛素抵抗性。
群药合力、多重作用,温阳、祛寒(因寒滞瘀)、荡热(因寒化火化热滞瘀)、涤痰(因寒湿生痰滞瘀)、利二便代谢血液中的垃圾及病理产物,降粘、溶栓、补肾、健脾、强心、护肝、理肺、润肠、活血化瘀、舒经通脉,温散寒凝,宣通上下阳气,内外通畅,气者,血之帅也,气通则血活,起到降血压、降血脂的作用。
本发明相比现有技术的优点在于:
(1)本发明中药组合物具有降血糖、降血压、降血脂功效,用于制备治疗高血糖、高血压、高血脂的各种食品、饮品、调味品、保健品或药品,且无副作用,病员耐受性好,安全有效;
(2)制备简单,价格低廉,疗效甚佳,适合各人类群的饮用、食用。
具体实施方式
下面对本发明的实施例作详细说明,本实施例在以本发明技术方案为前提下进行实施,给出了详细的实施方式和具体的操作过程,但本发明的保护范围不限于下述的实施例。
实施例1
本实施例的一种降血糖、降血压、降血脂的中药组合物,包括如下重量份数的原料:去皮桂枝15份,江油附子25份,炒莱菔子25份,车前子45份,野生马齿苋25份,葱白10份,肉桂10份,北苍术10份,炒南瓜子25份,大麦芽55份,醋北五味子6份,炒白芥子5份,炒紫苏子6份,炒桅子仁6份,楮实子8份,(剪头去尾)细辛4份,炒甜葶苈子10份。其中,所述去皮桂枝、江油附子、炒莱菔子、车前子、野生马齿苋为君药;葱白、肉桂、北苍术、炒南瓜子、大麦芽为臣药;醋北五味子、炒白芥子、炒紫苏子、炒桅子仁为佐药;楮实子、(剪头去尾)细辛、炒甜葶苈子为使药。
制备方法:
将去皮桂枝、江油附子、炒莱菔子、车前子、野生马齿苋、葱白、肉桂、北苍术、炒南瓜子、大麦芽、醋北五味子、炒白芥子、炒紫苏子、炒桅子仁、楮实子、(剪头去尾)细辛、炒甜葶苈子分别洗净,随后进行干燥、粉碎(粉碎至200目)、灭菌,备用;按照上述重量份数分别称取各原料进行混合,得目标所需中药组合物。
实施例2
本实施例的一种降血糖、降血压、降血脂的中药组合物,包括如下重量份数的原料:去皮桂枝18份,江油附子28份,炒莱菔子28份,车前子48份,野生马齿苋26份,葱白12份,肉桂12份,北苍术12份,炒南瓜子28份,大麦芽57份,醋北五味子7份,炒白芥子6份,炒紫苏子8份,炒桅子仁8份,楮实子10份,(剪头去尾)细辛5份,炒甜葶苈子13份。其中,所述去皮桂枝、江油附子、炒莱菔子、车前子、野生马齿苋为君药;葱白、肉桂、北苍术、炒南瓜子、大麦芽为臣药;醋北五味子、炒白芥子、炒紫苏子、炒桅子仁为佐药;楮实子、(剪头去尾)细辛、炒甜葶苈子为使药。
制备方法:
将去皮桂枝、江油附子、炒莱菔子、车前子、野生马齿苋、葱白、肉桂、北苍术、炒南瓜子、大麦芽、醋北五味子、炒白芥子、炒紫苏子、炒桅子仁、楮实子、(剪头去尾)细辛、炒甜葶苈子分别洗净,随后进行干燥、粉碎(粉碎至200目)、灭菌,备用;按照上述重量份数分别称取各原料进行混合,得目标所需中药组合物。
实施例3
本实施例的一种降血糖、降血压、降血脂的中药组合物,包括如下重量份数的原料:去皮桂枝20份,江油附子30份,炒莱菔子30份,车前子50份,野生马齿苋30份,葱白15份,肉桂15份,北苍术15份,炒南瓜子30份,大麦芽60份,醋北五味子10份,炒白芥子9份,炒紫苏子10份,炒桅子仁10份,楮实子12份,(剪头去尾)细辛6份,炒甜葶苈子15份。其中,所述去皮桂枝、江油附子、炒莱菔子、车前子、野生马齿苋为君药;葱白、肉桂、北苍术、炒南瓜子、大麦芽为臣药;醋北五味子、炒白芥子、炒紫苏子、炒桅子仁为佐药;楮实子、(剪头去尾)细辛、炒甜葶苈子为使药。
制备方法:
将去皮桂枝、江油附子、炒莱菔子、车前子、野生马齿苋、葱白、肉桂、北苍术、炒南瓜子、大麦芽、醋北五味子、炒白芥子、炒紫苏子、炒桅子仁、楮实子、(剪头去尾)细辛、炒甜葶苈子分别洗净,随后进行干燥、粉碎(粉碎至200目)、灭菌,备用;按照上述重量份数分别称取各原料进行混合,得目标所需中药组合物。
实施例4
本实施例的一种降血糖、降血压、降血脂的中药组合物,包括如下重量份数的原料:去皮桂枝23份,江油附子24份,炒莱菔子33份,车前子53份,野生马齿苋33份,葱白17份,肉桂17份,北苍术17份,炒南瓜子32份,大麦芽63份,醋北五味子12份,炒白芥子11份,炒紫苏子12份,炒桅子仁12份,楮实子14份,(剪头去尾)细辛7份,炒甜葶苈子18份。其中,所述去皮桂枝、江油附子、炒莱菔子、车前子、野生马齿苋为君药;葱白、肉桂、北苍术、炒南瓜子、大麦芽为臣药;醋北五味子、炒白芥子、炒紫苏子、炒桅子仁为佐药;楮实子、(剪头去尾)细辛、炒甜葶苈子为使药。
制备方法:
将去皮桂枝、江油附子、炒莱菔子、车前子、野生马齿苋、葱白、肉桂、北苍术、炒南瓜子、大麦芽、醋北五味子、炒白芥子、炒紫苏子、炒桅子仁、楮实子、(剪头去尾)细辛、炒甜葶苈子分别洗净,随后进行干燥、粉碎(粉碎至200目)、灭菌,备用;按照上述重量份数分别称取各原料进行混合,得目标所需中药组合物。
实施例5
本实施例的一种降血糖、降血压、降血脂的中药组合物,包括如下重量份数的原料:去皮桂枝25份,江油附子35份,炒莱菔子35份,车前子55份,野生马齿苋35份,葱白20份,肉桂20份,北苍术20份,炒南瓜子35份,大麦芽65份,醋北五味子14份,炒白芥子13份,炒紫苏子14份,炒桅子仁14份,楮实子16份,(剪头去尾)细辛8份,炒甜葶苈子20份。其中,所述去皮桂枝、江油附子、炒莱菔子、车前子、野生马齿苋为君药;葱白、肉桂、北苍术、炒南瓜子、大麦芽为臣药;醋北五味子、炒白芥子、炒紫苏子、炒桅子仁为佐药;楮实子、(剪头去尾)细辛、炒甜葶苈子为使药。
制备方法:
将去皮桂枝、江油附子、炒莱菔子、车前子、野生马齿苋、葱白、肉桂、北苍术、炒南瓜子、大麦芽、醋北五味子、炒白芥子、炒紫苏子、炒桅子仁、楮实子、(剪头去尾)细辛、炒甜葶苈子分别洗净,随后进行干燥、粉碎(粉碎至200目)、灭菌,备用;按照上述重量份数分别称取各原料进行混合,得目标所需中药组合物。
实施例6
本实施例的一种袋泡茶,采用上述实施例的降血糖、降血压、降血脂的中药组合物。
所述袋泡茶的具体制备方法为:将制得的所述降血糖、降血压、降血脂的中药组合物按计量9g/袋装入茶泡袋中。
此外,需注意的是,除了袋泡茶外,本发明降血糖、降血压、降血脂的中药组合物可广泛应用于食品、饮品、调味品、保健品、药品等各个领域;其中,当应用添加于食品时,可以是粥、面条、馒头、面包、饼干、月饼、糕点、粽子、大饼、冷食、膏类、米线、糖果等形式;当应用添加于饮品时,可以是酒、饮料等形式;当应用添加于调味品时,可以是食醋、酱油、调料粉等形式;当应用添加于保健品、药品时,可以是颗粒剂、片剂、胶囊、丸、口服液等形式。
试验例1
本试验例用于分析本发明降血糖、降血压、降血脂的中药组合物的具体活性成分及功能。
经实验,本发明原料配方的的中药组合物主要由生物碱、黄酮类、挥发油类、苷、酚类、多糖类等物质构成,经分析主要具有以下功能:
(1)促进DNA和蛋白质合成,抗氧化、抗缺氧、清除氧自由基、降低丙二醛含量、抑制脂质过氧化,提高一氧化氮(N0)含量和超氧化物岐化酶(SOD)活性。降低高脂血症模型大鼠血清TC、TG、LDL及AI水平,并能捉高HDL水平,具有调节高脂血症大鼠血脂代谢的作用。通过改善高脂血症的血脂代谢,使动脉指数下降,有效减轻主动脉壁粥样硬化形态学改变。总黄酮以浓度依赖性方式抑制大鼠主动脉平滑肌细胞(RASMC)增值,抑制氧化型低密度脂蛋诱导的RASMC增值,并可诱导少量RASMC凋亡,从而发挥抗动脉硬化作用。
(2)组合物多糖、苷类通过增加葡萄糖的利用,抑制细胞内氧化磷酸作用,干扰能量转移,改善2型糖尿病大鼠糖耐量和脂代谢紊乱,降低血清游离脂肪酸,减轻高胰岛素血症,提高胰岛素敏感性及活性,对四氧嘧啶所致糖尿病小鼠均具有降血糖作用,并能提高正常小鼠及四氧嘧啶所致糖尿病小鼠的糖耐量水。
(3)组合物中酚类、黄酮、生物碱、挥发油,使血管阻力下降,使脑、股动脉及下肢血流量增加,抑制氯化钾与肾上腺对离体胸主动脉条的收缩作用,不论肌内或静脉注射均有显著而持久的降压作用,水浸液给肾型高血压大鼠灌胃.亦有明显的降压作用,均可使血管阻力降低,血压下降。对高血压大鼠血管平滑肌Ca2+内流有抑制作用,对肠管平滑肌有松驰作用,并增加肢体血流量,椎体给药均有降压作用,该组合物除通过对血管的直接扩张作用而起降压作用外,并通过中枢神经系统发挥其降压作用。0.015~15mmol/L可舒张大鼠的主动脉,舒张血管,对血管紧张素抑制酶具有强抑制作用,产生降压效果。其体动脉收缩压(SAP)、舒张压(DAP)、体动脉平均压(MAP)、分别降低XXXmmHg、XXXmmHg、2.15.2mmHg、肺动脉收缩压(SPAP)、肺动脉舒张压(DPAP)、肺动脉平均压(MPAP)亦降低,使体血管组力(SVR)、肺血管阻力(PVR)明显降低。
试验例2
本试验例通过动物实验验证本发明降血糖、降血压、降血脂的中药组合物的应用疗效。
一、降脂实验
1、实验材料:SD大鼠(雌雄各半)体重200g左右,由来宝生物提供。
2、实验方法:
将SD大鼠分为“模型组”、“对照组”(后续饲喂地奥心血康片,成都地奥制药集团有限公司),“实验组”(后续饲喂本发明实施例3对应组合物);每组10只SD大鼠,且保证雌雄各半。
于河北雄安肽氏科技研发有限公司动物实验室饲喂室(清洁通风、光照温湿度适宜)内,先对三组SD大鼠饲喂高脂饲料配方(基础饲料68%,蛋黄粉10%,猪油10%,胆固醇12%)(各组大鼠自由采食),饲喂一周后测各组大鼠的总胆固醇和甘油三脂、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇含量。
接着,“模型组”灌服蒸馏水,“对照组”灌服地奥心血康片,“实验组”灌服本发明组合物药物。每日给药前小鼠称重,计算各组大鼠体重平均值,每日灌服两次,每次灌服20mg/g,实验时间为2周灌服结束后,12小时内禁食不禁水。分别测定血清中总胆固醇、甘油三酯、高密度脂蛋白和低密度脂蛋白水平。
3、实验结果。
结果如表1所示。
表1降脂实验结果
由表1结果可知,本发明组合物药物对降脂具有明显效果,且优于对照组的地奥心血康片。
二、降血糖实验
1、实验材料:SD大鼠(雌雄各半)体重200g左右,由来宝生物提供。
2、实验方法:
将SD大鼠分为“模型组”、“对照组”(后续饲喂消渴丸,广州白云山中一药业有限公司),“实验组”(后续饲喂本发明实施例3对应组合物);每组10只SD大鼠,且保证雌雄各半。
于河北雄安肽氏科技研发有限公司动物实验室饲喂室(清洁通风、光照温湿度适宜)内,先对三组SD大鼠给予高脂高糖饲料(含基础饲料65%、糖15%、蛋黄粉6%、胆固醇4%、脂肪加温后浸出的猪油10%)饲养28天,12小时禁食不禁水后,配制0.98%的四氧嘧啶生理盐水溶液按53.6mg/Kg的剂量进行尾静脉注射,48h后,禁食10h,检测三组大鼠的血糖值。
接着,“模型组”给予生理盐水,“对照组”给予消渴丸,“实验组”给予本发明组合物药物。灌胃给药,每天2次,早晚各一次。连续2周,2周后测定血糖值。
3、实验结果。
结果如表2所示。
表2降血糖实验结果
由表2结果可知,本发明组合物药物对降血糖具有明显效果,且优于现有的消渴丸。
三、降血压实验
1、实验材料:选用体重为90~120g±20g鼠,龄为2~3月的雄性SD大鼠。
2、实验方法:
将SD大鼠分为“模型组”(后续灌胃生理盐水)、“对照组”(后续灌胃13.5mg卡托普利/Kg/d),“实验组”(后续灌胃5g本发明组合物生药/Kg/d);每组10只SD大鼠。
用3%wubabituo钠腹腔注射大鼠10~15mim后,腹部清洁消毒,经腹正中纵形切口,依次钝性分离双侧肾动脉,用内径为0.3mm的自制环形银夹分别钳夹住双侧肾动脉起始部,成功完成手术后沫抹青梅素,闭合腹腔。局部涂抹青梅素吸收效果好、肌肉组织修复快,不易感染。有利于造模成功后血压长期稳定。术后一周用血压计检测大鼠尾动脉血压,每周1次,连续3周血压达到150±12.5㎜Hg,大部分血压己高于250mmHg±0.80。
“模型组”灌胃灌胃生理盐水,“对照组”灌胃13.5mg卡托普利/Kg/d,“实验组”灌胃5g本发明组合物生药/Kg/d;每天给药1次,连续给药3周,给药后1、2、3周测定血压。
3、实验结果:
结果如表3所示。
表3降血压实验结果
由表3结果可知,本发明组合物药物对降血压也具有明显效果,且优于对照组的卡托普利药物。
应用例1
牛某,男性,38岁,河北雄安人,就诊于河北大学附属医院,病案号831775。即往有高血压病史,有冠心病的危险因素,主因发作性胸闷,气短1年10个月,再发2个月就诊,查体:BP117/79mmHg,神清语利,口唇无紫绀,双肺呼吸音清,未闻及干湿性啰音:心侧向左侧扩大,心率114次/分,律齐,心音低钝,各瓣膜听诊区未闻杂音,腹软,无压痛,反跳痛及肌紧张,肝脾胁下未触及,下肢无水肿,神经系统查体未见异常。初步诊断为:1、扩张型心肌病,心力衰竭,心功能3级。2、高血压病3级,极高危。
入院后,完善各项辅助检查,电解质:钠130mmol/L;肾功:肌酐37umol/L;血常规:红细胞计数4.17x1012/L;静脉血糖:葡萄糖29.52mmol/L,血糖16.6mmol/L,糖化血红蛋白8.7%;患者血糖高,补充诊断:2型糖尿病。
内分泌科会诊调整血糖,1:严格执行糖尿病血糖饮食,定时定量,避免加餐。2,给予甘精胰岛素16u,睡前皮下注射;谷赖胰岛素早中晚各8u,餐前5分钟,监测血糖;尿常规:红细胞计数70.10/uL,隐血3+,尿蛋白4+;血脂:总胆固醇14.30mmol/L,甘油三酯52.43mmol/L,低密度脂蛋白胆固醇6.43mmol/L;肝功:r-谷氨酰基转移酶341U/L,天门冬氨基转移酶149U/L,丙氨酸氨基转移酶55U/L;充诊断:高脂血症。择期复查血脂、肝功示:总胆固醇8.72mmol,甘油三脂21.98mmol/L,低密度脂蛋白胆固醇5.33mmol/L,极低密度脂蛋白胆固醇2.01mmol/L,r-谷氨酰基转移酶268U/L,载脂蛋白B1001.68g/L,天门冬氨酸氨基转移酶175U/L,丙氨酸氨基转移酶127U/L,补充诊断:肝功异常。停用阿托伐他汀,给予阿利西尤单抗注射夜治疗,定期复查肝功血脂。甲功五项:三碘甲壮腺原氨酸0.73ng/mL。心肌酶谱,便常规未见异常。心脏彩超:1、左房增大左室内径高限值;2、室间隔及左室壁稍厚;3、三尖瓣少量返流;4、左室舒张功能减低。结合忠者症状、查体及辅助检查结果,综上诊断为:扩张型心肌病、心力衰竭、心功能3级;2、高血压病3级,极高危;3、2型糖尿病;4、高脂血症;5、肝功能异常。
住院期间,给予阿司匹林抗小板聚集,利尿剂减轻心脏负荷,西地兰强心。重组人脑利钠钛改善心功能,阿利西尤单抗注射液降脂、甘精胰岛素谷赖胰岛降血糖等治疗。经治疗病情仅有好转;继续口服药物:阿司匹林0.1g(1片),每晚1次,托拉塞米片5mg(1片),每早晨1次。螺内酯片20mg(1片)每早1次,富马酸比索洛尔片2.5mg(1片)每日3次。继续服用20天,各种指标没有任何下降改善。
对于上述患者,改用本发明中药组合物。
1、服用量为:每袋9g,每次2袋,每日2次。
服用方法:每日早晨,选将本发明组合物药物选将本发明组合物药物每袋9g(一次两袋,(实施例3配方)温水一次性口服,一天两次,随后再将9g的袋泡茶(实施例3配方,按照实施例6方法制备成袋泡茶)开水沏,待温度适口时饮用,一天2次,一次一袋,全天品品馀用。饮用10天检杳指标。
患者指标为,电解质:钠135mmol/L;肾功:肌酐48μmol/L;红细胞系数4.06x10十12/L,静脉血糖6.9mmol/L,糖化血红蛋白6.1%。总胆固醇6.3mmol/L,甘油三脂2.10mmol/L,低密度脂蛋白胆固醇3.68mmol/L。极低密度脂蛋白胆固醇1.12mmol/L。r-谷氨酰基转移酶58U/L,载脂蛋白B1.36g/L,天门冬氨基转移酶45U/L,丙氨酸氨基转移酶56U/L。根据以上指标评定有了很大改善。
2、为巩固疗效继续服用本发明中药组合物药物10日,每天2次,每次2袋,冲入沸水浸泡,饮服。
在经查检各项指标示为,电解质:钠135mmol/L;肾功:肌酐54μmol/L,纽细胞系数4.01x1012/L,血糖5.8mmol/L,糖化蛋白4.8%,总胆固醇5.1mmol/L,甘油三酯1.71mmol/L,低密度脂蛋白胆固醇3.31mmol/L,极低密度脂蛋白胆固醇1.03mmol/L。r谷氨酰基转移酶46U/L,载脂蛋白B1.16g/L,天门冬氨酸氨基转移酶38U/L,丙氨酸氨基转移酶47U/L。
经过20天泡茶饮用指标正常,延续饮用每日2袋(每袋9g),一次一袋。随访至今正常。
应用例2
尹女士,49岁,涞水县人,患高血脂、高血糖、高血压三年,曾服用二甲双胍、苯扎贝特、匹伐他汀、卡托普利等药物,仍控制指标不明显。血液检验总胆固醇6.6mmol/L,甘油三脂3.9mmol/L,血糖11.5mmol/L。
对于上述患者,改用本发明的中药组合物药物,服用药物配方、服用量及服用方法同应用例1。服用一个月后检测指标。
一个月后的患者指标为:总胆固醇3.8mmol/L,甘油三脂1.25mmol/L,血糖5.1mmol/L,指标正常,症状康复。
应用例3
王女士,29岁,潍坊市人,患者高血压、高血脂、高血糖18个月。服用本发明组合时前指标检测:静脉血糖13.80mmol/L,总胆固醇9.7mmol/L,甘油三脂16.5mmol/L,收缩压180mmHg,舒张压140mmHg。
服用本发明中药组合物药物(实施例3配方),每次50g温水冲服,每日2次,服用一周,效果显著。第二周,内服剂量调整为每次18g,日服2次。第3周剂量调为每次9g,每日2次,感觉身轻气爽,体况良好。
指标检测:血糖4.8mmol/L,总胆固醇3.98mmol/L,甘油三脂1.21mmol/L:收缩压120mmHg,舒张压80mmHg。经组合物药物成分中的多种代谢作用,指标趋于正常,恢复了健康。
应用例4
肖某,男,45岁,2021年7月18日就诊于容城县人民医院内-科门诊,门诊号:01448147,症状:肥胖,头晕、胸闷、气短。检查,BP160mmHg,肌酐26.5μmo1/L;红细胞数3.8x1012/L;静脉血糖15.6mmo1/L;糖化血红蛋白7.9%;总胆固醇8.9mmo1/L;甘油三脂3.98mmo1/L;高密度脂蛋白0.96mmo1/L;低密度脂蛋白4.57mmo1/L;r谷氨酰酸氨基转移酶79U/L;载脂蛋白1.678/L;天门冬氨酸转移酶79U/L;丙氨酸转移酶118U/L;诊断:高血压、2型糖尿病、高血脂症。用药:格列吡嗪1次1片,3次/日;阿卡波糖每次1片,3次/日;二甲双胍缓释片1次1片,1次/日;非诺贝特1次1片,3次/日;瑞舒伐他汀1次1片,1次/日;氨氯地平1次1片,1次/日。服药长达12个月10天,血压血糖时高也略有下降,症状稍有改善。2022年8月9日在容城县中医院内科门诊编号20220809000280。体检:BP140mmHg;肌酐74mol/L;红细胞数3x1012/L;静脉血糖9.86mmol/L;糖化血红蛋白7.4%;总胆固醇5.97mml/L;甘油三脂2.31mmol/L;转移酶63U/L;丙氨酸转移酶101U/L。
因长时间用药效果不显著,即改用本发明的中药组合物药物。
服用方法:
每次用18g组合物生药(实施例3配方),温水饮;3次/日;连续服用28天,头晕、胸闷、短气、血压症状缓解有显著疗效。
症状改变后,药用量每次9g中药组合物药物(实施例3配方),用量1次9g,2次/日,服用14天,进一步体检:保定市第一中心医院:体检号800928125,检测结果:BP120mmHg;肌酐81.80μmo1/L;静脉血糖5.2mmol/L;糖化血红蛋白5.1%;总胆固醇4.06mo1/L;甘油三脂1.47mmol/L;高密度脂蛋白胆固醇1.48;低密度脂蛋白胆固醇2.18;载脂蛋白1.1g;r谷氨酰酸氨基转移酶48U/L;天门冬氨酸氨基转移酶19.30U/L;丙氨酸氨基转移酶14.30U/L。
经本发明中药组合物药物的调节代谢功能,上述项指标正常,头晕、胸闷、短气.血压症状消失,相比于上述西药,见效快,治疗期短,效果确切。治愈率高。
应用对比实验例1
一、选择实验患者200例,分为“对照组”(选用降糖宁胶囊和消渴丸)和“实验组”(服用本发明组合物组,以实施例3为例)。
具体地,“对照组”(选用降糖宁胶囊和消渴丸)100人,其中,男50例,女50例,年龄在31~65岁。病程2~10年,病情程度:轻度29例,中度53例,重度18例。
“实验组”(本发明组合物组)100人,其中,男性50例,女性50例,年龄31~65岁。病程2~10年,病情程度:轻度21例,中度54例,重度25例。
二、实验治疗方法:
两组均正常饮食;同时,“对照组”口服降糖宁胶囊和消渇丸,一次各6片/粒,一日3次,温开水送下。“实验组”服用本发明中药组合物药物,一次服用50g,温水送服,一日2次。用药30天。
三、实验结果:
“对照组”(选用降糖宁胶囊和消渴丸)和实验组(本发明组合物)用药前、服用15日、服用30日的检测指标平均值如表4所示。
表4服用前后指标对比结果
其中,在服用药物15天后,对照组有着不同程度的病理改变。实验组对肥胖,口渴多饮,消渴善饥,多尿,倦怠乏力,自汗盗汗,烦热,尿浊,胸闷,气短,肿胀及皮肤的病理病等并发症效果显著。
在服用药物30天后,对整体治疗效果进行总结:
1、对照组:总数100例患者:显效14例,有效60例,康复6例,无效18例)总有效率82%,无效18%。
2、实验组:总数100例患者:治愈率98%,有效2%,总有效率100%。
综上可知,本发明中药组合物获得的降糖、降压、降脂活性成分,生物碱、黄酮类、挥发油类、酶类、活性多糖等物质,发挥着以疏为泄,以利为通,将肌体、膜原、半表半里、三焦、空肠管道、经络腧穴、皮里肉外、腠理毫毛的病理产物排出体外的作用。本发明燥热治消渴、降血糖、降血压、降血脂,气血遇热则行,经络遇热则通,寒遇热则温,湿遇热则散,风遇热则出,火遇热则解,痰遇热则化,虚遇热则壮。以温则泄,以温则疏,以温则利,以温则通,通则百病除。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.一种降血糖、降血压、降血脂的中药组合物,其特征在于,包括如下重量份数的原料:去皮桂枝15~25份,江油附子25~35份,炒莱菔子25~35份,车前子45~55份,马齿苋25~35份,葱白10~20份,肉桂10~20份,北苍术10~20份,炒南瓜子25~35份,大麦芽55~65份,醋北五味子6~14份,炒白芥子5~13份,炒紫苏子6~14份,炒桅子仁6~14份,楮实子8~16份,细辛4~8份,炒甜葶苈子10~20份;其中,所述去皮桂枝、江油附子、炒莱菔子、车前子、马齿苋为君药;所述葱白、肉桂、北苍术、炒南瓜子、大麦芽为臣药;所述醋北五味子、炒白芥子、炒紫苏子、炒桅子仁为佐药;所述楮实子、细辛、炒甜葶苈子为使药。
2.根据权利要求1所述的降血糖、降血压、降血脂的中药组合物,其特征在于,包括如下具体重量份数的原料:去皮桂枝18份,江油附子28份,炒莱菔子28份,车前子48份,马齿苋26份,葱白12份,肉桂12份,北苍术12份,炒南瓜子28份,大麦芽57份,醋北五味子7份,炒白芥子6份,炒紫苏子8份,炒桅子仁8份,楮实子10份,细辛5份,炒甜葶苈子13份。
3.根据权利要求1所述的降血糖、降血压、降血脂的中药组合物,其特征在于,包括如下具体重量份数的原料:去皮桂枝20份,江油附子30份,炒莱菔子30份,车前子50份,马齿苋30份,葱白15份,肉桂15份,北苍术15份,炒南瓜子30份,大麦芽60份,醋北五味子10份,炒白芥子9份,炒紫苏子10份,炒桅子仁10份,楮实子12份,细辛6份,炒甜葶苈子15份。
4.根据权利要求1所述的降血糖、降血压、降血脂的中药组合物,其特征在于,包括如下具体重量份数的原料:去皮桂枝23份,江油附子24份,炒莱菔子33份,车前子53份,马齿苋33份,葱白17份,肉桂17份,北苍术17份,炒南瓜子32份,大麦芽63份,醋北五味子12份,炒白芥子11份,炒紫苏子12份,炒桅子仁12份,楮实子14份,细辛7份,炒甜葶苈子18份。
5.一种如权利要求1~4任一所述的降血糖、降血压、降血脂的中药组合物的制备方法,其特征在于,包括如下步骤:
(1)将去皮桂枝、江油附子、炒莱菔子、车前子、马齿苋、葱白、肉桂、北苍术、炒南瓜子、大麦芽、醋北五味子、炒白芥子、炒紫苏子、炒桅子仁、楮实子、细辛、炒甜葶苈子分别洗净,随后进行干燥、粉碎、灭菌,备用;
(2)按重量份数分别称取各原料进行混合,得目标所需中药组合物。
6.根据权利要求5所述的降血糖、降血压、降血脂的中药组合物的制备方法,其特征在于,所述步骤(1)中,粉碎至200目后灭菌备用。
7.一种如权利要求1~4任一所述的降血糖、降血压、降血脂的中药组合物在食品、饮品、调味品、保健品、药品中的应用。
8.一种袋泡茶,其特征在于,采用如权利要求1~4任一所述的降血糖、降血压、降血脂的中药组合物。
9.根据权利要求8所述的袋泡茶,其特征在于,所述袋泡茶的具体制备方法为:将制得的所述降血糖、降血压、降血脂的中药组合物直接装入茶泡袋中。
10.根据权利要求9所述的袋泡茶,其特征在于,装入所述茶泡袋中的中药组合物计量具体为9g/袋。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311624084.1A CN117599140A (zh) | 2023-11-30 | 2023-11-30 | 一种降血糖、降血压、降血脂的中药组合物及其制备与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311624084.1A CN117599140A (zh) | 2023-11-30 | 2023-11-30 | 一种降血糖、降血压、降血脂的中药组合物及其制备与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117599140A true CN117599140A (zh) | 2024-02-27 |
Family
ID=89951234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311624084.1A Pending CN117599140A (zh) | 2023-11-30 | 2023-11-30 | 一种降血糖、降血压、降血脂的中药组合物及其制备与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117599140A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118236453A (zh) * | 2024-05-22 | 2024-06-25 | 广州市赛普特医药科技股份有限公司 | 包含红曲与银杏提取物的组合物在降低hdl-3中的应用 |
-
2023
- 2023-11-30 CN CN202311624084.1A patent/CN117599140A/zh active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118236453A (zh) * | 2024-05-22 | 2024-06-25 | 广州市赛普特医药科技股份有限公司 | 包含红曲与银杏提取物的组合物在降低hdl-3中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102836379B (zh) | 一种降脂解酒的中药复方制剂及其制备方法与应用 | |
CN103690919B (zh) | 用于治疗仔猪缺铁性贫血的药物及其制备方法 | |
CN101467582B (zh) | 九制益寿茶 | |
CN102784363A (zh) | 一种治疗胰腺癌的中药组合物及其制备方法 | |
CN102205107A (zh) | 一种治疗十二指肠溃疡的中药制剂及其制备方法 | |
CN103168883A (zh) | 可增强免疫力、抗病原微生物、抗病毒的茶饮料颗粒剂及其制备方法 | |
CN108524814A (zh) | 一种用于降低血糖的中药组合物及其制备方法 | |
CN108404019A (zh) | 复方菊苣根调节嘌呤代谢紊乱的固体制品及其制备方法 | |
CN105454576A (zh) | 茉莉花八宝茶及其制备方法 | |
CN117599140A (zh) | 一种降血糖、降血压、降血脂的中药组合物及其制备与应用 | |
CN110327421A (zh) | 一种适合宇航员具有提高精力和协调人体各器官功能的组合物 | |
CN105250913B (zh) | 一种治疗蛋鸡脂肪肝综合症的药物组合物 | |
CN109395028A (zh) | 一种预防、治疗三高症的葛景甲参酒配方及制备方法 | |
CN106994141B (zh) | 一种治疗便秘的中药组合物及其制备方法 | |
CN105267906A (zh) | 治疗、改善女性生理期与经期症候群的巧克力草本中药复方组合物 | |
CN106668811A (zh) | 黑枸杞抗癌救生片 | |
CN103100028A (zh) | 有利于降低酒精性肝损伤危害的软胶囊及其制备方法 | |
CN104888174A (zh) | 一种治疗脾胃虚寒型消化性溃疡的药物制剂及其制备方法 | |
CN102198261B (zh) | 一种治疗老年慢性结肠炎的中药制剂及其制备方法 | |
CN107712890A (zh) | 一种宁心安神膏滋及其制备方法 | |
KR100712659B1 (ko) | 당뇨병 및 이로 인한 합병증 치료 및 예방용 한약조성물 | |
CN106822660A (zh) | 一种治疗心脑血管疾病的中药制剂 | |
CN113662068A (zh) | 一种桂杞姜甘茶配方及其制备方法 | |
CN106177712A (zh) | 一种治疗心脑血管疾病的华蒜豆及其制备方法 | |
CN105617268A (zh) | 一种治疗鳞屑角化型脚气的药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |